



ENTERPRISES



AGRICULTURE/ENVIRONMENT

Aelred	66
Agdia Biofords	67
Algentech	69
Biométhodes	77
Global Bioenergies	95
WatchFrog	130



CONSULTANCY

Aurgalys	74
Bio Support	75



DIAGNOSTICS

BioSystems International	80
Endodiag	85
Genewave	91
GenoSplice technology	94
InGen BioSciences	100
IntegraGen	102
Statlife	123



MEDICAL DEVICES

Arterial Remodeling Technologies (ART)	71
AssistMov	72
Centaure Metrix	82
Novacyt	110
Tech Innovation	124
Theraclion	126



COMPUTING AND IT

Atrogene Research Bioinformatics	73
BioSolution	79
Oxalya	114




SCIENTIFIC INSTRUMENTATION

Flowgene	87
GenOptics	92
Physikron	118
SEBIA	120



R&D SERVICES AND PRODUCTS

Biomanufacturing Center	76
BioQuanta	78
Drugabilis	84
Genethon Bioprod	90
GenoSafe	93
Imagene	96
LPS BioSciences	103
MilleGen	107
New England Biolabs France	108
PartnerChip	115
PhenoPups	116
Phinc Development	117
Polytheragene	119
Sigma-Aldrich France	121
Texcell	125
XenTech	132



THERAPEUTICS

AISA Therapeutics	68
AMAbiotics	70
CECS/I-STEM - The Center for Stem Cell Studies	81
DNA Therapeutics	83
Epixis	86
GeneSignal	88
Genethon	89
Immune Pharma	97
Immunotherapix	98
Inatherys	99
InnaVirVax	101
LTKfarma	104
MAT Biopharma	105
Metabrain Research	106
Nokad	109
Novagali Pharma	111
Nutrivercell	112
ObeTherapy Biotechnology	113
Spheragen	122
Vaxon Biotech	127
Viroxis	128
VitamFero	129
Wittycell	131

Contact

Éric Lameignère

Director Genopole® Enterprises

eric.lameignere@genopole.fr





Aelred



FIELD OF ACTIVITY

- Custom gene mutation services for the generation and characterization of new alleles in any plant species.
- Development and supply of improved varieties (medicinal and fiber/bioenergy plants, in particular).

KEYWORDS

Reverse genetics - Plant biotechnology - Plant-based ingredients - Green chemistry and energy.

President Pierre Malvoisin

Contact details

Pépinière Genopole® Entreprises

4, rue Pierre-Fontaine - F-91058 ÉVRY Cedex

Tel. +33 1 60 87 89 00

E-mail contact@aelred.fr

Web site www.aelred.fr

Date of founding February 2009

Aelred offers its services to companies and public research laboratories wishing to obtain new alleles for a specific gene or confirm the function of a previously uncharacterized gene through reverse genetic tools. Research contracts are on-going with some companies, leaders in their sectors (seed, agro-ingredient and pharma businesses).

Starting from a collection of mutants (induced mutation), Aelred's technology enables the screening and characterization of plants mutated on a given gene (the candidate gene) in a relatively short time (one to two years, for an annual plant). These plants can be introduced thereafter in a conventional breeding program. The same technology can also be used on a natural variant library.

Aelred works in close collaboration with the INRA-URGV unit in Évry (*cf page 37*) that developed and improved this method and has licensed an INRA/Genoplante-Valor patent.

Aelred is also carrying out two in-house R&D programs: one to improve a medicinal plant, the objective being to commercialize safer, health-promoting ingredients extracted from this plant, and another one to develop a new biomass-plant used as renewable resources for energy and material.

Annual turnover: € 152 K (2010) > 3 salaried staff

Strengths: in-depth knowledge of an innovative plant genomics technology. Collaboration with its originator (INRA-URGV).

Innovation assets: IP/patent protection possible for a mutated gene.



| Agriculture/environment |

Agdia Biofords



FIELD OF ACTIVITY

Diagnostic kits for plant disease, genes of interest, GMOs, growth hormones.

KEYWORDS

GMO detection - Rapid diagnostic kit -
Detection of plant diseases - Agro-industry.

Manager & Scientific director **Dr Marc Masson**

In charge of International Sales & Marketing

Salima Berkani - Dr Marcos Amato

Contact details 5, rue Henri-Desbruères

Genavenir 8 - F-91030 ÉVRY Cedex

Tel. +33 1 60 78 81 64

E-mail info@biofords.com

Web sites www.biofords.com

Date of founding 28/11/1988

BACKGROUND

BIOFORDS was created in 1988 by Dr. Marc Masson, a former CSO at the vegetable seed company CLAUSE (selection of potatoes, forage crops and lawn grasses) with research experience at the University of Wisconsin (Madison, USA).

DESCRIPTION OF THE PRODUCTS SERVICES/TECHNOLOGY

Development and commercialization of detection kits for:

- // Plant pathogens (viruses, bacteria, fungi, viroids and phytoplasma).
- // Genetically modified organisms (GMOs: sweet corn, soya, canola, etc).
- // Plant growth hormones (auxins, abscissic acid, etc.).
- // Antibiotics.
- // Probes and molecular markers.

CUSTOMER REFERENCES

COLLABORATIONS/HIGHLIGHTS

- // The national French federation of potato plant producers.
- // INRA, CIRAD.
- // Universities and research institutes across Europe and the United States.
- // Agdia USA.
- // Phytotechnology Laboratories (USA).

COLLABORATIONS SOUGHT


We offer customized solutions to agrifood industry players:

- // Animal feed.
- // Horticulture, market gardening, nurseries, vineyards.
- // Trees and forests.
- // For crop protection industry with adapted detection disease kits.

Annual turnover 2009/2010 : €850 K > 6 salaried staff

Strengths: plant diseases and plant genetics (traits).

Innovation assets: development of kits with novel antibodies and quick PCR.



| Therapeutics |

AISA Therapeutics

FIELD OF ACTIVITY

AISA Therapeutics develops inflammation modulators. Applications concern (i) therapeutics for inflammatory and auto-immune diseases and (ii) anti-stress and anti-ageing nutraceuticals.

KEYWORDS

Anti-inflammatory - Anti-ageing -
Anti-stress - Vascular endothelium -
Nutraceuticals - Plant compounds.

BACKGROUND

AISA Therapeutics was spun out of a fundamental research program on novel anti-inflammatories at the Descartes University of Paris/Necker Children's Hospital. Since moving to the University of Paris 11 in 2002, AISA Therapeutics has identified and patented four plant molecules by using its *in vitro* and *in vivo* screening platforms. In 2007, one of these molecules (AISA 5203-L) gave rise (after preclinical evaluation of oral or topic administration) to two new patents covering tissue repair and the treatment of stress in the skin and the colon.

DESCRIPTION OF THE PRODUCTS SERVICES/ TECHNOLOGY

The company is developing its hit AISA 5203-L (D-limonene) and has filed three patents. Preclinical studies have revealed that AISA 5203-L has anti-inflammatory effects on the skin and the digestive system, as well as anti-stress properties. d-Limonene targets the adherence molecules in the vascular endothelium via a rhoA- dependent mechanism.

CEO Patrizia d'Alessio

Contact details

Pépinière Genopole® Entreprises
4, rue Pierre-Fontaine - F-91058 ÉVRY Cedex

Tel. +33 1 45 59 51 46 - +33 6 87 47 80 32

E-mail endocell@wanadoo.fr

Date of founding 19/10/2005

CUSTOMER REFERENCES COLLABORATIONS/HIGHLIGHTS

AISA Therapeutics is a partner in the European Union FP7 RISTOMED consortium, which aims at preventing ageing-related diseases by monitoring and managing healthy food and nutraceutical intakes in an elderly population (65 to 85 years of age). The expected impact of AISA 5203-L to lower circulating levels of the inflammatory markers is measured.

AISA forecasts several clinical studies oriented toward the demonstration of d-Limonene activity in similar populations, such as nurseries and pre-Alzheimer.

COLLABORATIONS SOUGHT

In 2011, AISA Therapeutics is focusing on the development and commercialization of an anti-stress and anti-inflammatory nutraceutical in the category: "for special medical purposes".

> 3 patents > 2 salaried staff

Strengths: a compound that can be exploited in the nutraceutical and pharmaceutical sectors.

Innovation assets: non-toxic anti-inflammatory compound, candidate for long-term treatments.



FIELD OF ACTIVITY

Development of innovative technologies for gene targeting and whole-genome transformation.

KEYWORDS

Gene targeting - Organelle Transformation - Genomics - Plant biotechnology.

BACKGROUND

Algentech SAS is using the technology developed over the last four years in the United Kingdom.

DESCRIPTION OF THE PRODUCTS SERVICES/TECHNOLOGY

Algentech develops three innovative technologies for the agro-biotech sector, biofuel production, the pharmaceutical industry and plant research.

Our innovative technologies enable precise targeting of genes in the plant nuclear and organellar genomes.

The nuclear gene targeting technology allows the rapid identification of genes associated with important agronomic traits. Chloroplast transformation is applied to production of high value compounds in plants such as biofuel precursors and plant-made pharmaceuticals.

The mitochondria transformation tool is a breakthrough technology used for induction of cytoplasmic-male sterility for production of high yield hybrid varieties.

President Alexander Sorokin

CSO Isabelle Malcuit

Contact details Headquarters

Pépinière Genopole® Entreprises

Campus: 1 - 4, rue Pierre-Fontaine

F-91058 ÉVRY Cedex

Laboratory Centre Inra de Versailles, Bât.4, RD10

Route de Saint-Cyr, F-78026 Versailles Cedex

Tel. +33 6 88 26 57 04 - +33 6 88 26 50 61

E-mails asorokin@algentech.com

imalcuit@algentech.com


Date of founding 18/03/2009

CUSTOMER REFERENCES COLLABORATIONS/HIGHLIGHTS

The company owns four patents and has signed two industrial contracts in 2010 with two leaders in the agro-biotech sector.

COLLABORATIONS SOUGHT

Algentech is targeting major plant biotech companies, seed companies and international research organizations.



| Therapeutics |

AMAbiotics



FIELD OF ACTIVITY

A partnering research organization (PRO) focused on understanding and exploiting interactions between microbial metabolism, food and health.

KEYWORDS

Bioremediation - Metabolism - Genomics - Bioinformatics - Aging - Reactive oxygen species.

BACKGROUND

AMAbiotics was incorporated to pursue the commercial development of metabolic bioremediation solutions based on (i) internationally acknowledged expertise developed over the years by Antoine Danchin and (ii) François Gendre's experience as Head of Research in a major food industry group.

DESCRIPTION OF THE PRODUCTS SERVICES/ TECHNOLOGY

AMAbiotics identifies metabolic interactions between communities of living organisms (including humans) in which each organism has a specific role—from indifference or collaboration through to competition or even aggression.

The community's overall equilibrium results from the exchange of chemical compounds (referred to as cenobiotics) that come either from food supplies or from the synthesis and degradation of compounds produced by the various species.

Understanding these metabolic cascades in specific situations (such as those created by long-term drug treatments, an unbalanced diet or the inevitable

consequences of aging) has enabled AMAbiotics to develop solutions for helping individual organisms to stay at or return to equilibrium. AMAbiotics develops proprietary or third-party products on the basis of a portfolio of know-how, patents and applications.

COLLABORATIONS/IMPORTANT FACTS

- // A member of the European Microme consortium (FP7).
- // Creation (with the Foundation Fourmentin-Guilbert) of the journal *Symplectic Biology* - rapid research notes in systems and synthetic biology.
- // Patents being filed and a number of high-level scientific publications.

COLLABORATIONS SOUGHT

AMAbiotics is looking for industrial alliances in the application of metabolic bioremediation (i.e. the correction of metabolic deficiencies in humans, animals and plants) in the fight against the negative effects of chemicals, chronic drug treatments and aging.

President Antoine Danchin

Director of Operations François Gendre

Contact details Genopole Campus 1
5, rue Henri-Desbrùères - F-91030 ÉVRY Cedex

Tel. +33 1 60 91 78 82

E-mail a.danchin@amabiotics.com

f.gendre@amabiotics.com

Web site www.amabiotics.com

Date of founding February 2010

> 5 salaried staff

Strengths: established expertise in the analysis of bacterial metabolism and the discovery of novel metabolic pathways. Close relationships with acknowledged partners worldwide - especially in Europe and Asia and in the field of genomics and its applications.

Innovation assets: a multidisciplinary approach to the overall metabolism of communities of organisms, combining *in silico* approaches (bioinformatics) and *in vivo* experimentation.



| Medical devices |

Arterial Remodeling Technologies (ART)



FIELD OF ACTIVITY

Arterial Remodeling Technologies ("ART") is developing bioresorbable peripheral and coronary artery stents that promote the natural post-angioplasty remodeling of an injured artery. In the mid- to long term, the company is seeking to diversify into the peripheral stent market. The company will remain flexible enough to produce custom stents according to the customer's blueprints.

KEYWORDS

Stent - Biocompatible - Bioresorbable - Polymer - Cardiovascular system.

CEO Machiel Van Der Leest

Contact details 3, rue de Verdun - Bât G

F-78590 NOISY-LE-ROI

Tel. +33 1 61 06 19 92

E-mail contact@art-stent.com

Web site www.art-stent.com

Date of founding 21/11/2001

BACKGROUND

The ART technology is based on IP generated at René Descartes University of Paris V (Professor Antoine Lafont), the Cleveland Clinic Foundation and CNRS Montpellier (Professor Michel Vert).

DESCRIPTION OF THE PRODUCTS SERVICES/TECHNOLOGY

ART is developing a new generation of bioresorbable stents for the treatment of coronary disease. In addition to having optimal mechanical properties, this stent dismantles itself gradually and degrades fully over time. This helps the artery to remodel itself and heal naturally by recovering its initial luminal profile. The goal is to replace permanently indwelling stents with bioresorbable, transient devices.

The polylactide stent has several advantages: it is non-inflammatory, biocompatible, hemocompatible and mechanically resilient.

Furthermore, ART's stents are (i) compatible with MRI, (ii) visible during angioplasty and (iii) do not require surgeons to change their surgical techniques and habits.

CUSTOMER REFERENCES COLLABORATIONS/HIGHLIGHTS

University of Montpellier 1, CNRS, University René Descartes Paris V.

> 1 granted patent + 9 patent applications > 6 salaried staff



| Medical devices |

AssistMov



FIELD OF ACTIVITY

ASSISTMOV designs innovative solutions for human rehabilitation, using robotics and virtual reality technology.

KEYWORDS

Rehabilitation - Physiotherapy - Robotics - Virtual reality - Mobility.

Project leader Mourad Bouzit

Contact details Pépinière Genopole® Entreprises

4, rue Pierre-Fontaine - F-91058 ÉVRY Cedex

Tel. +33 1 44 27 70 61

E-mail mourad.bouzit@assistmov.com

Web site www.assistmov.fr

Date of founding 01/10/2009

BACKGROUND

At the crossroad of physiotherapy, robotics and virtual reality, ASSISTMOV products and services re-invent the rehabilitation process, offering to physiotherapists highly innovative solutions, based on more than 18 years of research in France and US university labs.

DESCRIPTION OF THE PRODUCTS SERVICES/TECHNOLOGY

ASSISTMOV's first strategic orientation is set on lower limbs rehabilitation. Two products are currently being developed: a balance rehabilitation system and a walk rehabilitation system.

Prototypes already exist and the coming year will be dedicated to test and tune up the two devices, in order to market them at the end of 2011.

CUSTOMER REFERENCES COLLABORATIONS/HIGHLIGHTS

- // A prizewinner in the French Ministry of Research's 2008 business plan competition for innovative companies.
- // Company setup in Oct. 2009.
- // A prizewinner of Scientipole Initiative in 2010.
- // Two doctoral students in medical robotics join AssistMov team in October 2010.
- // Collaboration ASSISTMOV-ISIR (UPMC-Paris VI robotics lab).
- // Collaboration with various Physical Therapy and Functional Rehabilitation departments around Paris (Pr Thoumie at Rothschild hospital; Pr Bussel at Garches Hospital).
- // Partnership with RMI, the French leader in the computerization of the health system.

COLLABORATIONS SOUGHT

- // Industrial partnerships, to manufacture the devices (mechanics, electronics).
- // Commercial partnership, to supply our products in Western Europe.
- // Scientific collaborations in rehabilitation field.

> 3 patents + 2 in progress

Strengths: strong ability to design integrated solutions, using robotics and virtual reality. Close daily relations with scientific research in physical therapy and robotics.

Innovation assets: a multidisciplinary approach in robotics (mechanical, electronics and software engineering) along with a genuine industrial view.



Atragene Research Bioinformatics



FIELD OF ACTIVITY

Atragene Research Informatics provides innovative industrial solutions for integrating, managing and sharing data and line-of-business applications.

KEYWORDS

Bioinformatics - Cheminformatics - Web - Internet - Intranet - Extranet - Hygiene and safety - Software.

DESCRIPTION OF THE PRODUCTS SERVICES/TECHNOLOGY

Atragene Research Bioinformatics offers pharmaceutical and biotech companies IT solutions for integrating, managing and sharing data and line-of-business applications. Our job consists in helping you plan and implement the right IT solution.

We offer our customers a range of professional services for:

- /// The design and implementation of IT solutions for integrating, visualizing and analyzing biological and chemical data.
- /// The implementation of line-of-business software (electronic laboratory notebooks, LIMS, etc.) to capture, manage and archive large amounts of data.

CEO Alain Malpertuy

Contact details 33-35, rue Ledru-Rollin

F-94200 IVRY-SUR-SEINE

Tel. +33 1 77 01 80 65

E-mail contact@atragene.com

Web site www.atragene.com

Date of founding 20/11/2001

The benefits of ATRAGENE's high-value solutions include:

- /// The ability to access and share heterogeneous and dispersed data.
- /// Integrated and enhanced access to prediction and analysis tools.
- /// Automation of the *in silico* analytical process.
- /// Information capture and storage.

Atragene Research Bioinformatics offers a range of specialist products for information management and sharing:

- /// Atragene MSDS Manager for the management and intra-enterprise dissemination of safety data files.
- /// FTOPIA for secure online file sharing.



| Consultancy |

Aurgalys



FIELD OF ACTIVITY

Aurgalys provides operational and/or strategic support to life science and healthcare entrepreneurs and investors.

KEYWORDS

Corporate finance- Business development - Transition management - Support - Consulting.

Chief Executive Officer **Dr Philippe Berthon**

Contact details Pépinière Genopole® Entreprises

4, rue Pierre-Fontaine - F-91058 ÉVRY Cedex

Tel. +33 1 60 87 89 69

E-mail contact@aurgalys.com

Web site www.aurgalys.com

Date of founding March 2008

BACKGROUND

Founded by Dr Philippe Berthon, a scientist, manager and entrepreneur, Aurgalys leverages its know-how and network through its five partners and business affiliates based in Buenos Aires (Argentina), Tel Aviv (Israel), Lausanne (Switzerland) and Évry-Paris (France).

DESCRIPTION OF THE PRODUCTS SERVICES/ TECHNOLOGY

/// **Interim management:** CEO, CSO, regulatory affairs, CMO, marketing.

/// **Business development:** in/out licensing, joint ventures, distributions.

/// **Corporate finance:** fund raising, mergers & acquisitions, PIPE, alliances.

/// **Support/consulting:** strategy, due diligence, marketing.

CUSTOMER REFERENCES COLLABORATIONS/HIGHLIGHTS

Collectis, BioAlliance, Evolva/Arpida, NonLinear Tech, Medicen, Nanopowers, etc.

Strengths: corporate finance and consulting; entrepreneurs serving entrepreneurs.



| Consultancy |

Bio Support



FIELD OF ACTIVITY

A not-for-profit organization for sharing personnel between several companies.

KEYWORDS

Human resources - Sharing.

President Gregory Lemkine

Director Noëlle Couget

Contact details Pépinière Genopole® Entreprises
4, rue Pierre-Fontaine - F-91058 ÉVRY Cedex

Tel. +33 1 60 87 89 84

E-mail noelle.couget@biosupport.fr

Date of founding January 2006

BACKGROUND

A not-for-profit organization founded in 2006 on the initiative of six Genopole® companies, with a view to sharing key employees whom individual members could not afford to recruit on a full-time basis.

CUSTOMER REFERENCES COLLABORATIONS/HIGHLIGHTS

24 member companies.

DESCRIPTION OF THE PRODUCTS SERVICES/TECHNOLOGY

Shared human resources in finance, accountancy, quality management, IT and legal affairs and contract management.



> 7 salaried staff



| R&D services and products |

The Biomanufacturing center

FIELD OF ACTIVITY

Contract manufacturing of preclinical and clinical batches of biomolecules.

Genopole® has created a biomanufacturing center on its Evry campus. By using animal cell cultures, the center can produce a wide range of recombinant proteins (e.g. monoclonal antibodies).

The center is designed to produce preclinical and clinical batches for biotech companies and public-sector research labs.

Two independent cell culture suites enable the simultaneous production of two different biomolecules. In the future, the biomanufacturing center will operate under GMP certification of the French Regulatory Authorities (AFSSAPS).

The center will apply the most innovative techniques (notably single-use equipment) in order to reduce production costs and cross-contamination risks.

The initial commercial offering includes cell bank generation, process development and optimization, and research and preclinical batches production.

Contact Naceur Tounekti

Contact details Genopole Campus 1


5, rue Henri-Desbruères - Bât G8

F-91030 ÉVRY Cedex

Tel. +33 1 60 87 83 00

E-mail naceur.tounekti@genopole.fr

Web site www.genopole.fr





| Agriculture/environment |

Biométhodes

Biométhodes

FIELD OF ACTIVITY

Genetic engineering applied to bioenergy, green chemistry and industrial biotech.

KEYWORDS

Biomass - Biofuels - Biorefinery - Specialty enzymes.

BACKGROUND

- 1998-2000: development of the company's technology platform.
- 2000-2005: R&D collaboration with several major chemicals and pharmaceutical companies (ABEnzymes, GSK, Roquette, Sanofi-Aventis...).
- 2005-2007: development of biocatalysis and bioenergy applications.
- 2008-2011: collaboration between Biométhodes and Virginia Technology/Oak Ridge National Laboratory (US Department of Energy) on the development of the OPTAFUEL® bio refinery platform.

DESCRIPTION OF THE PRODUCTS SERVICES/TECHNOLOGY

Bio manufacturing system applied to industrial biotech. Genetic, protein and enzyme optimization.

The company has developed and exploited novel technologies (MM® and THR®) for improving industrial enzymes. These technologies are protected by three patent families owned by the company and parts of the work have been published in top-rank scientific journals.

Biométhodes owns patent pertaining to delignification and decrystallization of cellulose for which it has an exclusive and worldwide license from Virginia Tech.

CEO Gilles Amsallem

Development Director Raffy Kazandjian

Director of the US subsidiary OptaFuel

Anthony Scime

CSO Bruno Winter

Contact details Bât Genavenir 1
1, rue Pierre-Fontaine - F-91058 ÉVRY Cedex

Tel. +33 1 60 91 21 21

E-mail info@biomethodes.com

Web site www.biomethodes.com

Date of founding 06/11/1997

In order to achieve a full exploitation of any kind of ligno-cellulosic residues the company has developed a technological platform called OPTAFUEL®, which successfully integrates two crucial steps, the chemical pre-treatment and the biological hydrolysis.

OPTAFUEL® allows for the first time an optimal separation of the ligno-cellulosic biomass in its three various constituents, the lignin, amorphous cellulose and the hemicelluloses.

CUSTOMER REFERENCES COLLABORATIONS/HIGHLIGHTS

Development of the first process for transformation of lignocellulosic biomass into cellulose, hemicellulose, lignin, acetic acid. Implementation of the enzymatic hydrolysis of biomass.

Biométhodes signed a research contract with the Fraunhofer ICT (Germany) to scale-up the pre-treatment process.

Biométhodes received a public grant (USA) to develop a cellulosic ethanol biorefinery plant in South Virginia. The total value of this three years project is \$24 M.

COLLABORATIONS SOUGHT

Joint ventures in industrial chemistry, energy and the environment.

> 12 patents > 10 salaried staff

Strengths: intellectual property - industrial feasibility - well positioned in the USA and Europe.



| R&D services and products |

BioQuanta



FIELD OF ACTIVITY

- Service provision by leveraging innovative technologies in molecular modelling for the *in silico* ADME-T prediction and the *in vitro* investigation of metabolic function (mitochondrial respiratory chain / oxidative stress / energy status) for evaluating chronic toxicity.
- Discovery and development of new biomarkers and diagnostic kits.

KEYWORDS

Toxicity - ADME - Mitochondria - Oxidative stress - Services - Diagnostic - Therapeutics - Clinical care - R&D - Molecule - Research - Life science.

BACKGROUND

BioQuanta SA is a subsidiary of a group of companies dedicated to predictive and personalized medicine: delivering the right dose of the right drug to the right patient. BioQuanta SA is in charge of the group's diagnostics activities, from the provision of expert services through to kit development.

DESCRIPTION OF THE PRODUCTS SERVICES/ TECHNOLOGY

BioQuanta's *science as a service* offering targets pharmaceutical and cosmetic companies and all others concerned by the European Commission's regulation on the registration, evaluation, authorisation and restriction of chemical substances (REACH). Our two unique, complementary facilities provide accurate and reliable results to customers worldwide: MultiDIP® for the *in silico* prediction of ADME-T parameters for xenobiotic, and Mitoxis® for the *in vitro* evaluation of a

CEO Rémi Rabeuf
Business Development Manager for MultiDIP
Romain Guidon
Business Development Manager for Mitoxis
Marie Placines
Contact details 34, cours Blaise-Pascal - F-91000 ÉVRY
E-mail contact@bioquanta.net
Web site www.bioquanta.net
Date of founding 2003

compound's chronic toxicity and impact on cell metabolism. Combined use of the two facilities optimizes research work (with cost and time savings), drastically reduces the likelihood chance of development failures and makes it easier to categorize patients. Lastly, it fosters the development of safer, more effective drugs that can be delivered at the right dose to the right patient.

CUSTOMER REFERENCES COLLABORATIONS/HIGHLIGHTS

In July 2009, BioQuanta SA was listed on the Euronext Paris free market (ticker code: MLBQA). The company owns several patents and has a pipeline of six diagnostic kit projects that seek to fulfil unmet clinical needs. These patients have applications in life science research and clinical care through to industry (quality control). As a partner of the Paris Public Hospitals Group (AP-HP), BioQuanta SA is at the heart of academic/hospital/industrial network. The company is also a member of the "Medicen Paris Region" cluster.

COLLABORATIONS SOUGHT

Companies involved in the manufacture and distribution of patented diagnostic kits.

> 4 patents > 24 salaried staff

Strengths: a unique service offering worldwide. A product pipeline with multiple applications. Translational research at the academia/hospital/industry interface.

Innovation assets: novel, efficient decision support for R&D, covering a molecule's whole life cycle – from discovery to the drug.

Other facts: BioQuanta is part of a group of companies dedicated to predictive and personalized medicine.



| Computing and IT |

BioSolution



FIELD OF ACTIVITY

Consultancy and service provision: a specialist in IT solutions for the integration, management and analysis of biological data.

KEYWORDS

LIMS - Data management - Information systems - Data analysis.

Director Alain Merceron

Contact details Pépinière Genopole® Entreprises
4, rue Pierre-Fontaine - F-91058 ÉVRY Cedex

Main site 202, quai de Clichy
92110 CLICHY-SUR-SEINE

Tel. +33 1 46 85 28 60

E-mail contact@biosolution.fr

Date of founding 04/10/2006

BACKGROUND

Since 2006, BioSolution has been providing support for all phases of IT system design and development. In 2009, BioSolution merged its business activities with those of SPLIMS (an exclusive LabVantage partner for French-speaking markets and a supplier of LIMS for research, clinical trials, quality control and production in many industrial sectors).

DESCRIPTION OF THE PRODUCTS SERVICES/TECHNOLOGY

- Lab automation, biological sample tracking and robot integration. Integration of high-throughput biological platforms.
- Deployment of life science information systems (document management systems, reporting systems, web portals, etc.).
- Design and development of scientific databases, data integration.

CUSTOMER REFERENCES COLLABORATIONS/HIGHLIGHTS

BioSolution specializes in the integration of heterogeneous biological data and is a Gold Partner for Talend Open-Source ETL solutions.



Strengths: very good knowledge of biotech, computing expertise.

Innovation assets: the use of open-source software bricks.



| Diagnostics |

BioSystems International



FIELD OF ACTIVITY

Research, validation and qualification of cancer and Alzheimer Disease biomarkers with the goal of developing products for diagnostics and research.

KEYWORDS

Biomarker - Diagnostics - Monoclonal antibody - Plasma.

BACKGROUND

BSI was founded in 2004 by six former members of Pfizer's genomics and bioinformatics division in Fresnes. In 2010, BSI merged with the Parisian company MicroBioChips, specialists in antibody microarrays. The company now has a total of 35 employees based at the Évry Genopole® and in Hungary.

DESCRIPTION OF THE PRODUCTS SERVICES/TECHNOLOGY

Discovery and validation of biomarkers for cancer and chronic diseases using a proteomics technology platform based on proprietary, large scale monoclonal antibody libraries. The antibodies are generated against human plasma proteins and then undergo high-throughput screening.

Development and commercialization of cancer diagnostics based on small panels of monoclonal antibodies.

Development and commercialization of research tools consisting of monoclonal antibody microarrays made against human plasma proteins and associated services.

CEO Jean-Pierre Tirouflet

CSO, General director Laszlo Takacs

CFO Élisabeth Rocolle-Teyssier

Contact details Bât Genavenir 1

1, rue Pierre-Fontaine - F-91058 ÉVRY Cedex

Tel. +33 1 64 98 20 00

E-mail info@biosys-intl.com

Web site www.biosys-intl.com

Date of founding 16/05/2004

CUSTOMER REFERENCES COLLABORATIONS/HIGHLIGHTS

Launch of the development of a diagnostic test for lung cancer.

The merger with the Parisian company MicroBioChips, specialists in antibody microarrays.

Development and launch of a series of monoclonal antibody microarrays made against human plasma proteins (PlasmaScan™) for research use.

COLLABORATIONS SOUGHT

BSI is seeking partners for the development, production and commercialization of cancer diagnostics generated in their in-house research programs. BSI is also seeking clients for their monoclonal antibody microarrays and associated services.

> 35 salaried staff





| Therapeutics |

CECS / I-Stem The Center for Stem Cell Studies



FIELD OF ACTIVITY

Evaluation of the full technological and therapeutic potential of pluripotent stem cells (from all sources) for treating monogenic diseases. The CECS is notably developing substitutive cell therapies for degenerative pathologies and stem cells for use as targets in drug screening.

President Karl-Stéphane Robert

Director Raymond Zakhia

Contact details CECS/I-Stem : Genopole Campus 1
5, rue Henri-Desbrùères - F-91030 ÉVRY cedex

Tel. +33 1 69 90 85 20

E-mail sfacchinato@istem.fr

Date of founding 01/10/2009

BACKGROUND

CECS (founded in 2009) is a not-for-profit R&D organization dedicated to the development and application of stem-cell-based technologies and treatments in the field of rare genetic diseases. The CECS is fully funded by the French Muscular Dystrophy Association (AFM) as part of the I-STEM Institute (*cf page 29*).

DESCRIPTION OF THE PRODUCTS SERVICES/TECHNOLOGY

The CECS has developed several therapeutic research themes in the field of muscle diseases as part of I-STEM's activities, together with four technological research programs:

- // Stem cell biotechnology (large-scale cell production, genetic engineering and medium-throughput screening).
- // High-throughput screening.
- // Functional genomics (development of gene product based technological tools for studying monogenic diseases).
- // iPS disease modeling (the use of induced pluripotent stem cells as a new tool in drug screening).

CUSTOMER REFERENCES COLLABORATIONS/HIGHLIGHTS

- // A collaborative research program funded by Oseo.
- // A collaborative research contract with Roche.

COLLABORATIONS SOUGHT

Industrial collaborations.

Operating budget: €4 M/year
> 8 patents > 11 publications > 45 salaried staff



| Medical devices |

Centaure Metrix



FIELD OF ACTIVITY

Centaure Metrix produces and sells diagnostic and therapeutic devices for gait disorders, with applications in medicine (rehabilitation, physical medicine, neurology, myology, geriatrics, rheumatology, etc.) and sports training.

KEYWORDS

Medical equipment - Gait - Rehabilitation - Sport.

CEO Dr Bernard Auvinet

CSO Dr Éric Barrey

Contact details

170, bd des Champs-Élysées - F-91000 ÉVRY

Tel. +33 1 64 57 70 07

E-mail direction@centaure-metrix.com

Web site www.centaure-metrix.com

Date of founding 18/10/2001

BACKGROUND

Founded in 2001 by a scientist and a rheumatologist. A prizewinner in the French Ministry of Research's business plan competition for innovative companies and a member of the Entrepreneurs network and the Medicen Paris Region cluster.

DESCRIPTION OF THE PRODUCTS SERVICES/TECHNOLOGY

// **LOCOMETRIX diagnostics:** solutions for evaluating and quantifying gait disorders and running style and performance; assessment of the risk of falls in the elderly.

// **LOCOMETRIX feedback training:** a treadmill-based, active rehabilitation method.

// **LOCOMETRIX podology:** a solution for evaluation the comfort of soles.

// **EQUIMETRIX:** a solution for quantifying locomotor parameters in four-legged animals: limps and fitness for racing.

CUSTOMER REFERENCES COLLABORATIONS/HIGHLIGHTS

Centaure Metrix is actively involved in clinical studies with the Pierre Fabre group (fibromyalgia, hyaluronic acid), the Institut de Myologie (human, canine and feline muscular dystrophies), Liege University Medical Center (Alzheimer's disease) and the Pays de la Loire University Medical Center (the PREPA study on prediction of the risk of falls in the elderly).

COLLABORATIONS SOUGHT

// **Research partners:** evaluation of the risk of falls in the elderly, early detection of Alzheimer's disease, clinical evaluation of therapies for Parkinson's disease.

// **Commercial partners:** healthcare companies, mutual health insurers, distributors.

Annual turnover: €125 K > 1 patent > 3 salaried staff

Strengths: a leader in accelerometry-based gait analysis.

Solid scientific and clinical validations of the technology.

Innovation assets: rapid results, portable equipment and applicable in routine practice.





| Therapeutics |

DNA Therapeutics



FIELD OF ACTIVITY

Development of a new class of target therapy, Anticancer drugs.

KEYWORDS

Cancer - Treatment-related resistance - DNA repair - Signal interfering DNA (siDNA) - Target therapy - Anticancer drug.

CEO & Chairman Jian-Sheng Sun

Contact details Pépinière Genopole® Entreprises
4, rue Pierre-Fontaine - F-91058 ÉVRY Cedex

Tel. +33 1 60 87 89 01

E-mail contact@dna-therapeutics.com

Web site www.dna-therapeutics.com

Date of founding 08/06/2006

BACKGROUND

DNA Therapeutics is a clinical stage biopharmaceutical company that was spun out of several French public research institutions (the Curie Institute, CNRS, INSERM and the French National Natural History Museum).

DESCRIPTION OF THE PRODUCTS SERVICES/TECHNOLOGY

DNA Therapeutics is developing a new class of drugs which deals with tumor resistance to conventional therapies, such as radiotherapy, chemotherapy. In fact, the efficacy of anticancer therapies often is limited by tumor cells' enhanced DNA repair capacity which confers resistance to treatment.

CUSTOMER REFERENCES COLLABORATIONS/HIGHLIGHTS

In collaboration with public research partners, DNA Therapeutics has obtained *in vivo* proofs of concept of the efficacy of its first product (Dbait) as an adjuvant to radiotherapy or chemotherapy.

Dbait's mechanism of action and specific biomarkers have been elucidated and identified respectively. The first-in-human trial has been initiated since september 2011.

COLLABORATIONS SOUGHT

- // A strategic alliance with a pharmaceutical company after the achievement of clinical proof of concept.
- // Sublicensing and early co-development agreements with partners for defined geographic territories, in emerging markets or in animal healthcare.

> 5 patents > 10 salaried staff

Strengths: adjuvant molecules for radio- and chemotherapy.

Innovation assets: unique, patented, breakthrough technology that has been validated in the animal.



| R&D services and products |

Drugabilis



FIELD OF ACTIVITY

Evaluation of pharmaceutical drugability in early-phase R&D: experimental support and consultancy for the evaluation and selection of highly drugable candidates.

KEYWORDS

Early formulation - Salt selection - Polymorphism - Lead optimization - Selection of drug candidates - Preformulation - Crystallization.

BACKGROUND

// **2006:** Accredited for France's research tax credit.

// **2007:** Winner of the "Trophée Espoirs de l'Économie" award (Hauts-de-Seine Chamber of Commerce and Industry - 2nd prize)

// **2009:** Drugabilis joins the Board of Directors and the Executive Board at the Medicen Paris Region Biocluster.

DESCRIPTION OF THE PRODUCTS SERVICES/TECHNOLOGY

Drugabilis studies the physico-chemical and biopharmaceutical profiles of new chemical entities and drug delivery systems *via* lead optimization programs, early formulation for animal studies, salt selection, preformulation and polymorphism studies. Drugabilis is the only French CRO to have this type of characterization platform for supporting early-stage research.

Strengths: unique expertise in drugability at the research/development interface, a particularly comprehensive characterization platform and highly experienced staff. Micro-methods suited to the constraints of today's research programs. novel methodologies, responsiveness, flexibility and rapid service.

Innovation assets: the formulations developed for animal studies can be produced, characterized and dispatched in real time on the test sites. Drugabilis' regular customers benefit from a special mode of interaction which accelerates day-to-day collaboration and research program support.

CEO & CSO Joel Vacus

COO Isabelle Menier

Contact details 5, rue Jean-Baptiste Clément

F-92290 CHÂTENAY-MALABRY

Tel. +33 1 46 61 28 50

E-mail contact@drugabilis.com

Web site www.drugabilis.com

Date of founding October 2004

CUSTOMER REFERENCES COLLABORATIONS/HIGHLIGHTS

Drugabilis has already worked for more than 70 different customers including: Genfit, Ipsen, Pfizer, DNDi, Guerbet, Phenex, Genkyotex, Trophos, PreGlem, HRA Pharma, Anaconda Pharma, Bio Alliance Pharma, Fovea Pharmaceuticals Wittycell... The company is also a partner in the AD-Inov collaborative project (supported by the "Nutrition Santé Longévité" Lille-Region Biocluster).

COLLABORATIONS SOUGHT

Drugabilis offers its services to (i) biotech companies seeking to accelerate their research and secure the pharmaceutical development of their drug candidates and (ii) pharmaceutical companies looking for skilled, well-equipped and flexible contractors.



| Diagnostics |

Endodiag



FIELD OF ACTIVITY

The design, development and marketing of medical devices and services for the diagnosis of endometriosis.

KEYWORDS

Diagnostics - Endometriosis - Medical Device - Biomarker - Pharmacotesting

CEO Cécile Real

Contact details Pépinière Genopole® Entreprises

4, rue Pierre-Fontaine - F-91058 ÉVRY Cedex

Tel. +33 1 60 87 89 29

E-mail cecile.real@endodiag.com

Web site www.endodiag.com

Date of founding January 2011

BACKGROUND

Endodiag is the result of over 20 years of endometriosis research by Drs Bouquet de Jolinière and Gogusev (INSERM unit U1016) and underpinned by several international publications, together with extensive knowledge of medical device and gynecology markets from the two other company founders.

DESCRIPTION OF THE PRODUCTS SERVICES/TECHNOLOGY


A specialist in endometriosis diagnosis. The company notably develops medical devices for the biopsy of endometriosis lesions and provides an associated sample analysis service.



> 1 patent > 2 salaried staff

Strengths: 20 years of research, a complementary management team and a target market with unmet needs.

Innovation assets: a unique sampling device, novel cell lines and genotypic and phenotypic markers.



Epixis

Epixis



FIELD OF ACTIVITY

Epixis is developing vaccines based on a new generation of virus-like particles (called "e-VLPs") targeting infectious agents. Epixis also acts as a service provider for serum screening (neutralizing antibody assays).

KEYWORDS

VLP - Vaccine - DNA vaccine - Infectious disease - Neutralizing antibody.

President Charlotte Dalba, M.D., Ph.D

Contact details 16-18, rue de la Glacière

F-75013 PARIS

Tel. +33 1 42 17 65 20

E-mail cd@epixis.com

Web site www.epixis.com

Date of founding 23/07/2003

BACKGROUND

Since 2004, Epixis has:

- // put together a world-class group of specialist staff;
- // built a portfolio of five patent families (based on IP from the CNRS, INSERM, the Pierre & Marie Curie University of Paris and the Pasteur Institute) covering a vaccine technology which is applicable to many different infectious diseases;
- // validated the e-VLP platform against hepatitis C;
- // validated the e-VLP platform against a second virus;
- // established a unique serum screening service platform.

DESCRIPTION OF THE PRODUCTS SERVICES/TECHNOLOGY

Epixis has developed the e-VLP technology platform for vaccine production. The e-VLP platform combines the efficacy of VLPs (such as those used in Gardasil® and Cervarix® vaccines) with a much greater degree of flexibility in particle design.

Epixis' e-VLPs can potentially express all types of viral envelope proteins. The e-VLPs replicate the natural virus perfectly and thus induce an appropriate immune response.

CUSTOMER REFERENCES COLLABORATIONS/HIGHLIGHTS

The first vaccine candidate (a therapeutic vaccine for hepatitis C) has been validated in mouse and monkey and is ready to start regulatory preclinical development. During the year 2010, the technology was successfully applied to a second (confidential) target in collaboration with an American company.

COLLABORATIONS SOUGHT

Epixis is seeking additional partners to lead the preclinical and Phase I/IIa clinical development of its first vaccine candidate and to apply the e-VLP technology to other infectious diseases.

Annual turnover: €544 451 > 5 patents > 6 salaried staff

Strengths: a team with acknowledged expertise, a solid patent portfolio. A unique technology platform that is applicable to many infectious diseases, including some with very significant markets.

Innovation assets: e-VLPs combine the efficacy of VLPs (such as those used in Gardasil® and Cervarix® vaccines) with a much greater degree of flexibility in particle design.



Flowgene

Flowgene



FIELD OF ACTIVITY

Analytical instrumentation: detection of laser-induced native and/or Raman fluorescence (with a 224 nm laser).

KEYWORDS

Fluorescence - 224 nm laser - HPLC - Capillary electrophoresis - Odor detection.

CEO Bruno de Vandière

Contact details Rond-Point du Biopôle
F-63360 SAINT-BEAUZIRE

Tel. +33 4 73 64 43 69

E-mail b.de.vandiere@flow-gene.com

Web site www.flowgene.com

Date of founding 11/12/2001

BACKGROUND

// **2003:** filing of a patent on the use of an elliptical cell to collect a fluorescence signal.

// **2005:** filing of a patent for the detection of odors (detection of a conformational change in a protein).



DESCRIPTION OF THE PRODUCTS SERVICES/ TECHNOLOGY

- // Odor detector (2006).
- // The HPLC 224 LINP detector (2008).
- // Capillary electrophoresis detector (2008).

CUSTOMER REFERENCES COLLABORATIONS/HIGHLIGHTS

- // A development contract with the US Department of Defense on an odor detector.
- // A development contract on a capillary electrophoresis detector.

COLLABORATIONS SOUGHT


The detection, identification and counting of bacteria in suspension.

Annual turnover (2009): € 500 K > 3 patents > 2 salaried staff

Strengths: in-depth knowledge of laser-induced native the Raman fluorescence (with a 224 nm laser). Strong patent position.

Innovation assets: the only company to have mastered this detection technology.

Other facts: a second-generation detection cell is being developed.



| Therapeutics |

GeneSignal



FIELD OF ACTIVITY

Based on its portfolio of over 90 genes specifically involved in angiogenesis, Gene Signal designs, validates and develops innovative therapeutic solutions for pathologies related to angiogenesis regulation.

KEYWORDS

Rejection of corneal grafts - Anti-angiogenics - Antisense oligonucleotide - Retinopathy - Oncology.

BACKGROUND

GeneSignal was founded in 2000 at Genopole®. Although GeneSignal International is now based in Switzerland, the company is pursuing its research program in Évry and its development activity in Canada.

DESCRIPTION OF THE PRODUCTS SERVICES/TECHNOLOGY

GeneSignal is focusing its development on niche markets. Its first drug candidate (for the prevention of corneal graft rejection) is in Phase III clinical development.

The company is evaluating three other drug candidates with applications in dermatology and ophthalmology and is also working on four promising molecules in the field of vascular disease.

COLLABORATIONS SOUGHT

In order to focus on research, GeneSignal is currently seeking potential licensees for commercializing or co-developing its therapeutic portfolio.

CSO Salman Al-Mahmood

Contact details Pépinière Genopole® Entreprises
4, rue Pierre-Fontaine - F-91058 ÉVRY Cedex

Tel. +33 1 60 87 89 41 / 89 35

E-mail sam@genesignal.com

Web site www.genesignal.com

Date of founding 11/02/2000





FIELD OF ACTIVITY

The discovery, development and production of innovative therapies for rare genetic diseases in general and neuromuscular diseases in particular.

KEYWORDS

Rare diseases - Biotherapies - Neuromuscular diseases - Gene therapy, cell therapy - Gene-based therapeutics - Vector technology, gene transfer, stem cells - Pharmaceutical development - Regulatory affairs - Preclinical and clinical development - GMP production of gene transfer vectors (at a dedicated Gene and Cell Therapy Establishment, the ETGC).

Genethon is a not-for-profit biotherapy company. Over 80% of its budget is provided by the French Muscular Dystrophy Association (the AFM), thanks to donations from France's annual Téléthon. Genethon's goal is to provide gene therapies to patients suffering from rare genetic diseases in general and neuromuscular diseases in particular.

Genethon is a leading global player in the discovery and development of treatments for rare and orphan diseases. Genethon is also a major stakeholder in the biotherapy field. With help from Genopole® and the local authorities, Genethon is building the "Genethon Bioprod" biomanufacturing centre which, when opening in 2011, will be the world's largest facility for the production of gene therapy vectors.

Genethon's scope of action encompasses all the expertise and skills involved in the discovery, clinical development and biomanufacturing of gene therapy vectors. This particularly includes:

- // A GMP biomanufacturing department capable of producing clinical batches of drug candidates for gene therapy trials. This department also comprises staff with expertise in bioprocess R&D, pharmaceutical development and analytical control.
- // An *in vitro* and *in vivo* drug testing platform, including:
 - An animal house hosting up to 4000 rodents.
 - A functional investigation facility.
 - An imaging and cytometry platform, with tools and skills for molecular and physiopathological investigation, from the single cell to the whole animal level (cf page 57).
 - A histology service.
- // Drug development departments, whose mission is to investigate gene therapy approaches in the animal (cf page 26).
- // A group working on the immunologic aspects of gene therapy.

President Laurence Tiannot-Herment

CEO Frédéric Revah

General Secretary Stéphane Roques

CSO Philippe Moullier

Director Product Development and Bioproduction Mehdi Gasmi

Contact details 1 bis, rue de l'Internationale

BP 60 - F-91002 ÉVRY Cedex

Tel. +33 1 69 47 28 28

E-mail frevah@genethon.fr

Web site www.genethon.fr

Date of founding 1990

- // A group working on the identification and development of biological markers and theranostics for monitoring neuromuscular diseases [Duchenne muscular dystrophy, in particular].
- // A national DNA and cell biobanking facility (cf page 51).
- // A Regulatory and Clinical Affairs department (design, implementation and management of clinical trials).
- // A Quality Assurance group.

Genethon is also partner in the "Advanced Diagnostics for Novel Approaches Therapeutics" (ADNA) program coordinated by the Mérieux Alliance. This strategic industrial collaboration (part-funded by OSEO, the French state innovation agency) includes bioMérieux and GenoSafe in the field of diagnostics and Genethon and Transgene in the field of therapeutics. The project is designed to contribute to the development of personalized medicine by making novel biodiagnostics and new therapies available to healthcare stakeholders.

Thanks to its "DNA School", Genethon also provides training throughout the year on methods and issues in genomics and DNA science.

- > 2 new patents filed in 2010
- > 23 scientific publications
- > 220 staff
- > 2 clinical gene therapy trials underway and a portfolio of drug candidates at various stages of preclinical development



| R&D services and products |

Genethon Bioprod



FIELD OF ACTIVITY

GMP clinical batches for gene therapy products.

KEYWORDS

GMP production of vectors for gene transfer -
Biomanufacturing - Clinical trials.

President Laurence Tiennot-Herment

Chief Executive Officer Frédéric Revah

Director Product Development and Bioproduction

Mehdi Gasmî

Contact details 1 bis, rue de l'Internationale

BP 60 - F-91002 ÉVRY Cedex

Tel. +33 1 69 47 28 28

E-mail mgasmî@genethon.fr

Web site www.genethon.fr

Date of founding 2011

Genethon Bioprod, which is scheduled to open in Q4 2011, will be the new production center of GMP grade gene therapy products for clinical trials of Genethon.

Located on Genopole's® campus in Évry, it was constructed thanks to co-financing by AFM (€5,5 M), Genopole® (€8 M), Île-de-France Local Council (€8 M) and the General Council of the Department of Essonne (€7 M) for a global building budget of €28,5 M.

Thanks to its operational area and production scales, Genethon Bioprod is the largest bioproduction center worldwide for clinical grade gene therapy products.

Genethon will have an yearly production capacity of close to twenty clinical batches produced yearly for trials conducted in France and abroad to treat from several to few hundreds of patients depending on the pathology targeted and on the specific product manufactured.

KEY DATA

- /// **5 000 m²** dedicated to the biomanufacturing and quality control of gene therapy products.
- /// Approximately **2 500 m²** classified and confined laboratories [L3 confinement adapted to viral products and GMO handling].
- /// **4 production suites** of 500 m².
- /// Production of **20 clinical grade** batches of gene therapy product per year at full capacity.
- /// 2 suites for aseptic filling in Class A isolators.
- /// Up to **800 l of bioreactor cultures** for AAV (4 bioreactors of 200 l each).
- /// Up to 100 l of culture for lentiviral vectors.
- /// 120 m² pilot laboratory dedicated to process industrialization.
- /// 500 m² of quality control laboratories in accordance with Quality regulations.
- /// 15 different HVAC engines to provide clean air to the various production zones.
- /// Green standards: Genethon Bioprod fulfills HEQ® (High Environmental Quality) requirements.
- /// Annual operating cost: from €5 to 8 M funded by AFM thanks to the donations of Téléthon.





| Diagnostics |

Genewave



FIELD OF ACTIVITY

Genewave is a fast growing Molecular Diagnostic Company which is developing and manufacturing Rapid Diagnostic Tests based upon its proprietary platform, GeneSpress™ and primarily focused on Antibiotics Resistance issues.

KEYWORDS

Molecular diagnostics - Infectious diseases - Resistance - Antibiotics - Nosocomial Infections.

BACKGROUND

In January 2010, Genewave has merged with Serial Genetics (Évry-based Company), thus acquiring new technical expertise into the development of CE-IVD marked diagnostics kits.

Genewave's offer is now addressing three market segments:

/// **Life Science** for which Genewave has developed several innovative products: the microarray product line called Amplislides™, the Hyblive™ genotyping Platform and the Droplive System that performs qPCR from Single Cells.

/// **Diagnostics**, Genewave is now offering an unique system called GeneSpress™ that allows fast, multiplexed and integrated molecular diagnostic. Genewave has also developed the DiagArray microArray Reader and is currently developing several CE-IVD tests for various conditions (Thrombosis and Antibiotic Resistance).

/// **Biodefense**, Genewave is developing a portable and ultra-sensitive identification system based on the GeneSpress™ platform to rapidly identify pathogens in air.

> 10 patents > 25 salaried staff

Strengths: world-class multidisciplinary team, design of multiplexed molecular diagnostics tests together with fully integrated diagnostic platforms.

President François-Xavier Desforges

Contact details

Headquarters and

Manufacturing Center:

Bât Genavenir 8

5, rue Henri-Desbrùères - F-91030 ÉVRY Cedex

Tel. +33 1 60 77 45 16 - Fax +33 1 60 77 96 39

Site R&D 172, rue de Charonne - 75011 PARIS

Tel. +33 1 55 25 17 00 - Fax +33 1 55 25 17 10

E-mail info@genewave.com

Web site www.genewave.com

Date of founding February 2002

DESCRIPTION OF THE PRODUCTS SERVICES/TECHNOLOGY

Several CE-IVD diagnostic tests running on the GeneSpress™ platform are under development to help clinicians and patients fight several pathological conditions:

/// Evaluation of the Thrombosis Risk

Thrombo inCode is a diagnostic test that evaluates the risk of Deep Thrombosis by combining a dozen markers into a single kit and offering an improved diagnosis based upon patient symptoms and genotype. The Test will be CE-IVD marked in Q2 2011 and will be commercially available through our exclusive distributor, Ferrer inCode.

/// Antibiotics Resistance

A couple of tests using GeneSpress™ for a rapid identification of pathogens and associated resistances and a patient's resistance to several antibiotics is developed within the framework of the OSEO-ISI funded program NOSOBIO. The tests should be CE-IVD marked in Q3 2012 and Q3 2013.

CUSTOMER REFERENCES COLLABORATIONS/HIGHLIGHTS

Gendiag, Thales Security Systems, academic labs and hospitals in Europe.

COLLABORATIONS SOUGHT

/// Majors and SMEs in the diagnostic market to co develop multiplex diagnostic kits.

/// Biopharmaceutical companies that have developed drug specific biomarkers and need companion diagnostic tests to support the drug development process from inception through to regulatory approval and launch.



GenOptics

GENOPTICS
BIO INTERACTIONS

HORIBA
Scientific

FIELD OF ACTIVITY

Design and manufacture of scientific instruments for the analysis of biomolecular interactions using surface plasmon resonance imaging (SPRI). Expert analysis and service provision in biomolecular analysis.

KEYWORDS

SPRI - Label-free - Bio-interaction - Multiplexing.

BACKGROUND

GenOptics was founded in 2001 as a result of work performed at the Optics Institute in Orsay and the French Atomic Energy Commission (CEA) in Grenoble. In April 2009, the company became a subsidiary of HORIBA Jobin Yvon, which is based in Longjumeau (near Paris).

DESCRIPTION OF THE PRODUCTS SERVICES/TECHNOLOGY

Genoptics provides complete Label free bio-affinity solutions, from blank biochip consumable to ready to use functionalized and spotted dedicated biochips.

With real time monitoring of hundred different interactions, our affinity analysers are the most advanced solutions today supported by a highly specialized team.

CEO Didier-Luc Brunet
Contact details GENOPTICS SA (HORIBA Scientific)

Tel. +33 1 69 74 86 33

E-mail contact@genoptics-spr.com

Web site www.genoptics-spr.com

Date of founding 27/08/2001

CUSTOMER REFERENCES COLLABORATIONS/HIGHLIGHTS

GenOptics has special collaborations with several R&D groups, such as the French military procurement agency and the CEA.

GenOptics works on biochips with several international groups. Focused on life science applications, GenOptics collaborates with the Universities and recently filed for a patent on the interfacing of SPRI with MALDI-TOF mass spectrometry, in collaboration with Évry's University. Thus providing researchers with easier access to the identification and quantification of new biomarkers.

A new milestone was reached in late 2009, with the release of the enhanced SPRI PlexII affinity analyzers offering enhanced performance and novel functions (interaction temperature control, automated continuous-flow injection and a more user-friendly interface).

Annual turnover: €600 K > 5 patents > 12 salaried staff

Strengths: flexibility. Expert instrumentation skills for the study of biomolecular interactions.

A multidisciplinary team of graduate and PhD scientists and engineers. An international distribution network.

Innovation assets: SPRI-mass spec coupling.



| R&D services and products |

GenoSafe

GENOSAFE

FIELD OF ACTIVITY

GenoSafe is a Contract Services Organization which specializes in evaluating the efficacy, quality and safety of innovative biotherapeutic products. We meet our clients' specific needs by performing custom studies in strict compliance with regulatory requirements.

KEYWORDS

Gene transfer - Gene therapy - Cell therapy - Vaccination.

BACKGROUND

GenoSafe was incorporated in 2003 and became operational in 2004. Its two shareholders are Généthon (*cf page 89*) and the French Muscular Dystrophy Association (AFM).

DESCRIPTION OF THE PRODUCTS SERVICES/TECHNOLOGY

From the research phase through to the clinic, GenoSafe offers true project support in study design, methodological development & validation and product testing in four main fields:

- // Molecular analysis (including biodistribution studies for gene transfer products).
- // Evaluation of immune responses.
- // Quality control of gene and cell therapy products for preclinical and clinical use.
- // Follow-up of patients included in clinical trials.

President Stéphane Roques

Business development director Vincent Zuliani

Study director Dr Muriel Audit

Contact details 1, rue de l'Internationale

BP 40064 - F-91002 ÉVRY Cedex

Tel. +33 1 69 47 11 57

E-mail contact@genosafe.com

Web site www.genosafe.com

Date of founding 03/09/2003

CUSTOMER REFERENCES COLLABORATIONS/HIGHLIGHTS

- // GenoSafe's European clientele is composed of biotech firms, pharmaceutical companies and academic labs.
- // GenoSafe is a partner in various French and European collaborative projects.
- // GLP compliance certificate.

COLLABORATIONS SOUGHT

Clients seeking a CSO to assess the safety, quality and efficacy of their biotherapeutic products, responding to their expectations in terms of Quality of Services (scientific and regulatory) and meeting the timelines.

> 15 salaried staff

Strengths: scientific expertise in complementary fields, customized services, flexibility, ability to meet timelines, GLP compliance, facilities: BSL1, BSL2 and BSL3 labs.

Innovation assets: customer support from the research phases through to the clinic.



GenoSplice technology



FIELD OF ACTIVITY

Bioinformatics service provision (gene expression, splicing).

KEYWORDS

Splicing - Bioinformatics - DNA chips - Expression - High-throughput sequencing - RNA-Seq.

BACKGROUND

The company has been spun out of the European Alternative Splicing Network of Excellence (EURASNET).

DESCRIPTION OF THE PRODUCTS SERVICES/TECHNOLOGY

GenoSplice has developed high-performance analysis tools for processing the data generated by transcriptomics techniques (DNA microarrays, exon skipping, gene tilling, high-throughput sequencing, etc.).

Services provided:

- // Analysis of gene expression, including splicing.
- // Biological interpretation tools (interfaces, databases, etc.).
- // Custom bioinformatics services: signaling pathway analysis, motif searching, clustering, probe design for custom chips, etc.

Co-managers

Pierre de la Grange, Marc Rajaud

Contact details

GenoSplice technology
Centre Hayem - Hôpital Saint-Louis
1, av. Claude-Vellefaux - F-75010 PARIS

Tel. +33 1 57 27 68 39/42

E-mail contact@genosplice.com

Web site www.genosplice.com


Date of founding 12/11/2008

CUSTOMER REFERENCES COLLABORATIONS/HIGHLIGHTS

- // Prizewinner in the French Ministry of Research's 2008 and 2011 business plan competition for innovative companies.
- // Funding from BIOCRITT and OSEO.
- // A member of the Medicen Paris Region cluster.
- // Collaborations: INSERM, IGR, Pasteur Institute, CNRS, Curie Institute, University of Kentucky, University of Cambridge, University of Newcastle, Howard Hughes Institute, St-Jude Hospital.

COLLABORATIONS SOUGHT

Gene expression, in particular at the exon-scale.





GLOBAL BIOENERGIES

FIELD OF ACTIVITY

Global Bioenergies is developing a bioprocess for converting renewable resources into gaseous hydrocarbons (light alkenes: isobutene, propylene, butadiene, ethylene, straightchain butane, etc.).

KEYWORDS

Biofuel - Bioenergy - Renewable Resources - Isobutene - Synthetic Biology.

BACKGROUND

Global Bioenergies was incorporated in 2008 by Marc Delcourt and Philippe Marlière. It is one of the few companies worldwide (and the only one in Europe) working on biological processes for gaseous hydrocarbon production.

PRODUCTS/SERVICES/TECHNOLOGY

The process is based on setting up an artificial metabolic pathway (designed by the company) in various micro-organisms and using renewable resources (sugars from sugar cane, sugar beet, starch or agricultural and forestry waste).

Since the hydrocarbon products are gaseous, no purification steps (such as distillation, in the case of ethanol) are required. This should lead to significantly improved environmental and economic parameters as compared to those of today's existing biofuel production approaches. By using proven, cheap, chemical processes, these gaseous alkenes can then be easily converted into liquid hydrocarbons (petrol, kerosene, diesel, ETBE, etc.) and various polymers (for use in tires, organic glasses and plastics). The company has reached the first development milestones in its isobutene production process ahead of schedule: proof of concept, strain design and a lab-scale prototype. Global Bioenergies is continuing to improve its process yield and is getting ready to perform tests in a pilot plant. In parallel, the company is seeking to repeat

Chairman and CEO Marc Delcourt

Process designer and Chairman of the Scientific Advisory Board Philippe Marlière

Contact details Genopole Campus 1
5, rue Henri-Desbrères - F-91030 ÉVRY Cedex

Tel. +33 1 64 98 20 50

Fax +33 1 64 98 20 51

E-mail info@global-bioenergies.com

Web site www.global-bioenergies.com

Incorporation date 17/10/2008

this success with other gaseous alkenes (propylene, butadiene, ethylene, straight-chain butane, etc. – all pivotal molecules in petrochemistry that are currently only derived from crude oil).

HIGHLIGHTS

Global Bioenergies performed its first round of financing in early 2009 (raising €4 M with Masseran Gestion, the venture capital subsidiary of Caisse d'Épargne bank) and a 2,9 fold oversubscribed IPO in June 2011. It has created a top-level Scientific Advisory Board, built a team of 20 researchers and obtained proof of concept for its process. In late 2010, the company opened an office in Munich and signed its first contract (with an American company) on a particular application of its process in a billion-dollar market. In July 2011, Global Bioenergies entered into a strategic bio-butadiene partnership with Synthos, a leading East-European chemicals company. The company works in close collaboration with the Genoscope lab (the CEA Genomics Institute) and thus has access to unique facilities and expertise for sequencing, metagenomic cloning and synthetic biology. Global Bioenergies also collaborates with the joint UEVE/CEA/CNRS LAMBE laboratory.

COLLABORATIONS SOUGHT

Global Bioenergies is seeking to establish industrial collaborations and grant options on future, application-specific, exclusive licenses on its technology.

> 20 salaried staff

Strengths: a bioprocess based on the creation of a new, artificial metabolic pathway; major environmental and economic value.

Innovation assets: biomanufacturing of gaseous hydrocarbons.



imagene

FIELD OF ACTIVITY

- Services and products for long-term DNA storage at room temperature using encapsulation.
- Complementary DNA extraction services.
- R&D on the preservation of biological material at room temperature.

KEYWORDS

DNA and RNA storage - Room temperature - Long-term - Industrial process - Gene library.

BACKGROUND

Imagene has developed and obtained a worldwide patent for a novel, encapsulation-based technology for the unlimited-term conservation of DNA at room temperature.

DESCRIPTION OF THE PRODUCTS SERVICES/ TECHNOLOGY

The Imagene technology is based on controlled atmosphere encapsulation of pre-purified and desiccated DNA which is then protected from degradation factors by storage in compact, sealed, corrosion-proof metal capsules. It is thus possible to store the DNA of any species in a form compatible with any type of current or subsequent analysis. Our breakthrough innovation has many advantages over conventional (cryostorage) methods, particularly in terms of stability, safety, operating & maintenance costs, transport and distribution.

Imagene markets services and products for long-term preservation of DNA at room temperature and complementary services of DNA extraction and QC analysis. Imagene's offer is a global solution for DNA preservation and use.

Imagene has successfully conducted a program aimed at applying its technology for the preservation of DNA at room temperature to RNA samples.

CEO Sophie Tuffet

Contact details Headquarters:

Bât Genavenir 6 - Genopole Campus 1
5, rue Henri-Desbruères - F-91030 ÉVRY Cedex

Branch office: Parc scientifique Unitec

1 - 2, allée du Doyen-Brus - 33600 PESSAC

Tel. +33 1 60 77 62 22

E-mail imagene@imagene.fr

Web site www.imagene.fr

Date of founding 01/12/1998

For key customers in need of processing large numbers of samples, Imagene would be amenable to sell and install a complete platform.

CUSTOMER REFERENCES COLLABORATIONS/HIGHLIGHTS

/// An industrialized, automated technology platform applicable to the large-scale treatment of genetic material (2,500 DNA capsules a day, i.e. 500,000 a year).

/// Ensures full, lasting traceability of each biological sample and meets quality standards (ISO 9001: 2000, ISO 17025).

/// Many scientific collaborations, including the Institut Bergonie, the Pasteur Institute, the French National Natural History Museum and the French National Crime Research Institute (IRCGN).

COLLABORATIONS SOUGHT

With its encapsulation facility now operational, Imagene is seeking industrial partners and customers (academic labs, biotech firms and pharmaceutical laboratories) interested in taking advantage of room temperature storage for their DNA samples.

4 patent families, 3 of which were filed in 2008 > 12 salaried staff

Strengths: the only technology for stable DNA storage at ambient temperature.

Innovation assets: compatible with all types of DNA analysis and handling methods.



| Therapeutics |

Immune Pharma



Immune Pharma
Targeted Medicine

FIELD OF ACTIVITY

The biotech company Immune Pharma SAS is developing therapeutic monoclonal antibodies (mAbs) with applications in the fields of cancer, autoimmune and inflammatory diseases and transplantation.

KEYWORDS

Monoclonal Antibodies – mAbs, *Fully human*,
Cancer – Autoimmunity – Transplantation.

President and CSO Jean Kadouche

CEO Daniel Teper

Tel. +33 6 89 86 84 18

E-mail j.kadouche@immunepharma.com

Web site www.immunepharma.com

Date of founding 18/12/2010

BACKGROUND

The biotech company Immune Pharma SAS is developing therapeutic mAbs. It was incorporated in order to leverage the in-depth expertise of its two founders (Daniel Teper, CEO, and Jean Kadouche, President and CSO) in this field.

DESCRIPTION OF THE PRODUCTS SERVICES/TECHNOLOGY

- /// A fully human anti-eotaxin 1 mAb in Phase 2b clinical trials in Crohn's disease (licensed from ICO Therapeutics Inc.).
- /// A fully human anti-Fas mAb in the preclinical development phase for GVHD and toxic epidermal necrolysis/Lyell syndrome (co-development with IMED).
- /// A technology for generating *fully human* mAbs: HuCell®.
- /// Immunonanoparticles (INPs-mAb) in the treatment of solid tumors, leukemias and lymphomas.
- /// Dual-epitope mAbs against EGFR receptors.

CUSTOMER REFERENCES COLLABORATIONS/HIGHLIGHTS

- /// Anti-eotaxin 1, licensed from ICO Therapeutics Inc.
- /// Anti-Fas, co-development with IMED.
- /// Partnering with the Hebrew University of Jerusalem (Yissum): INPs-mAb, Professor Simon Benita.
- /// Partnering with the Weizmann Institute (Yeda): dual-epitope mAbs against EGFR receptors, Professor Yossi Yarden.
- /// A technology for generating fully human mAbs: HuCell®, IP.

COLLABORATIONS SOUGHT


mAb or technology licensing (fusion proteins, expression systems, drug delivery, cytotoxicity and labeling) with intellectual property, freedom to operate and proof of concept.

> 9 patents > 3 salaried staff

Strengths: mAbs and drug development experience. Management team, know-how and new targets.

Innovation assets: HuCell® *fully human* technology.

Other facts: the company's business model and selected targets.



| Therapeutics |

Immunotherapix



Immunotherapix

FIELD OF ACTIVITY

Development of biologics based on the immune properties of mycobacteria cells, for the treatment of severe, chronic, inflammatory diseases.

KEYWORDS

Immunotherapy - Regulatory T cells - Severe, chronic, inflammatory diseases.

President, CSO Pr Gilles Marchal

Contact details BioTop Institut Pasteur

28, rue du Docteur-Roux - F-75724 PARIS Cedex 15

Tel. +33 1 45 68 86 68

E-mails g.marchal@immunotherapix.com

Date of founding September 2008

BACKGROUND

Immunotherapix is a Pasteur Institute spin-out founded by Professor Gilles Marchal, Micheline Lagranderie and Professor Hervé Bercovier. The company won a prize in France's 2008 national business plan competition for innovative technology companies.

DESCRIPTION OF THE PRODUCTS SERVICES/TECHNOLOGY

Immunotherapix is developing an immunotherapy product that induces the *in vivo* differentiation of regulatory T cells - resulting in a long-acting yet reversible and well-tolerated anti-inflammatory effect in animal models of asthma, Crohn's disease and other autoimmune diseases.

CUSTOMER REFERENCES COLLABORATIONS/HIGHLIGHTS

In December 2010, the company signed its first collaborative R&D agreement with an international pharmaceutical company.

COLLABORATIONS SOUGHT

Immunotherapix is seeking financial partners for the clinical development of its lead product in the long-term treatment of severe asthma.



> 5 salaried staff

Strengths: strong IP. A multidisciplinary team with extensive experience in research and drug development.

Innovation assets: a new therapeutic class that combines a potent, long-acting anti-inflammatory effect with a favorable safety profile.



| Therapeutics |

Inatherys



FIELD OF ACTIVITY

Development of therapeutic monoclonal antibodies for clinical applications in the field of inflammation and oncology.

KEYWORDS

Monoclonal antibodies - Antibody fragments - Inflammation - Orphan disease - Innovative mechanism of action.

BACKGROUND

Inatherys is a spin-off of two research units: INSERM U699-Renal immunopathology, receptors and inflammation and of UMR 8147-cytokines, immune response and hematopoiesis, which is associated with the Onco-hematology department of the Necker hospital. Inatherys is a cutting-edge, scientifically driven company with a pronounced dedication and commitment to therapeutic antibodies. Founders of Inatherys produced, characterized and patented a portfolio of monoclonal antibodies with a candidate drug for leukemia and lymphoma and another candidate drug for severe inflammatory diseases.

DESCRIPTION OF THE PRODUCTS SERVICES/TECHNOLOGY

Inatherys identified two new therapeutic targets for immunotherapy of severe orphan diseases :

▮ The transferrin receptor CD71: Inatherys developed a candidate drug, INA01 antibody (anti-CD71) that showed its efficacy in pre-clinical studies in the therapy of three incurable orphan oncohematological diseases: the adult T cell leukemia (ATLL) caused by HTLV-1, the Mantle cell lymphoma (MCL) and acute myeloblastic leukemia (AML).

▮ The receptor for the Fc portion of Immunoglobulin A, the CD89: Inatherys developed and validated three "leads" molecules (Fabs anti-CD89) for treatment of

CEO Coralie Belanger

Contact details Pépinière Genopole® Entreprises
4, rue Pierre-Fontaine - F-91058 ÉVRY Cedex

Tel. +33 6 01 13 58 59

Date of founding 04/06/2009

severe inflammatory diseases involving monocytes and macrophages. Inatherys explored the potential therapeutic application of the targeting of CD89 in an orphan disease: the Macrophage Activation Syndrome (MAS), but also in more common severe inflammatory diseases such as asthma, glomerulonephritis and rheumatoid arthritis not responding to conventional therapy.

Inatherys feeds its portfolio with new products created by a platform for the validation and optimization of monoclonal antibodies. Inatherys has also the expertise to test the identified "leads" on relevant animal models for cancer and inflammatory diseases.

CUSTOMER REFERENCES COLLABORATIONS/HIGHLIGHTS

Inatherys obtained the proof of concept *in vivo* and *ex vivo* of its first product, the INA01, and also identified its mechanism of action. A toxicological exploratory study in monkeys was performed. The phase I clinical trials of INA01 are scheduled for early 2013.

COLLABORATIONS SOUGHT

Inatherys is seeking for financial partners to continue the preclinical and clinical development of its two candidate drugs. A strategic alliance with a pharmaceutical company after obtaining the first proof of concept in patients for the two leads is conceivable.

> 2 patents > 2 salaried staff

Strengths: 2 candidate drugs in development.

Innovation assets: Platform for the identification of new "leads". Handling of animal models relevant in cancer and inflammatory diseases. Expertise *in vivo/ex vivo* validation and development of monoclonal antibodies.



FIELD OF ACTIVITY

The InGen BioSciences group is formed by two complementary entities: an R&D laboratory specializing in the discovery and development of bacterial antigens (as the basis for novel *in vitro* diagnostic tests in infectious serology) and a marketing and distribution subsidiary that sells proprietary and third-party *in vitro* tests and instruments for the diagnosis of human diseases.

KEYWORDS

Infectious diseases - Immunology - Antigenes - Multiplexed diagnostics.

BACKGROUND

InGen Biosciences (formerly AbAg) was founded in 2001 and closed rounds of fundraising in 2003 (€2 M) and 2005 (€6 M).

DESCRIPTION OF THE PRODUCTS SERVICES/ TECHNOLOGY

InGen BioSciences focuses on the discovery and development of novel bacterial antigens by leveraging proteomics technologies. These antigens form the basis of new-generation *in vitro* diagnostic tests. InGen markets these and other products in the fields of infectious disease and immunology. InGen notably has a leading position in the latter market.

CUSTOMER REFERENCES COLLABORATIONS/HIGHLIGHTS

Thanks to its expertise in bacterial antigens, InGen BioSciences has developed an innovative, multiplexed, serological approach. For example, the non-invasive, first-generation BJI Inplex™ assay can detect staphylococcal infections on bone and joint prostheses and is faster than conventional tests.

InGen BioSciences collaborates with reference centers for bone and joint infections in the design and validation of its assays.

COLLABORATIONS SOUGHT

InGen BioSciences seeks to forge synergistic, strategic alliances based on its R&D skills and the group's other areas of expertise.

CEO Isabelle Buckle

Contact details 17, avenue du Parc

F-91380 CHILLY-MAZARIN

Tel. +33 1 69 79 64 80

E-mail ibuckle@ingenbiosciences.com

Web site www.ingenbiosciences.com

Date of founding 28/11/2001

Annual turnover: €21 000 K > 38 patents filed > 65 salaried staff

Strengths: a responsive company with a good reputation among hospital-based and private-practice medical biologists. A strong, attractive business model (R&D and distribution).

Innovation assets: multiplexed serodiagnostics.



| Therapeutics |

InnaVirVax



FIELD OF ACTIVITY

InnaVirVax is developing (i) innovative biotherapies for the treatment of HIV infections and cancer and (ii) a prognostic test for the onset of AIDS in seropositive patients.

KEYWORDS

HIV - AIDS - Therapy - Biotherapies - Prognosis.

BACKGROUND

InnaVirVax's projects have been spun out of the UMR-S 945 Immunity and Infection Laboratory (a joint INSERM-Pierre & Marie Curie University of Paris research unit) at the Pitié Salpêtrière Medical Center.

InnaVirVax was founded by Professor Patrice Debré, Dr Vincent Vieillard and Dr Joël Crouzet in order to develop new anti-HIV therapies on the basis of a breakthrough discovery.

InnaVirVax is also developing a novel biotherapy in the field of cancer.

DESCRIPTION OF THE PRODUCTS SERVICES/TECHNOLOGY

- /// A new therapy for HIV-1 infected patients, protecting the immune system from the CD4 + T lymphocyte depletion, in synergy to antiretrovirals.
- /// A prognostic test for the prediction of immunodepression and the monitoring of HIV patients.
- /// A passive immunotherapy for immunodeficiency in treatment-failure HIV-1 patients.
- /// An innovative cancer immunotherapy.

CEO Joël Crouzet, Ph.D.

Contact details Pépinière Genopole® Entreprises
4, rue Pierre-Fontaine - F-91058 ÉVRY CEDEX

Tel. +33 1 60 87 89 40

E-mail contact@innavirvax.fr

Web site www.innavirvax.fr

Date of founding March 2008

CUSTOMER REFERENCES

COLLABORATIONS/HIGHLIGHTS

- /// InnaVirVax was a prizewinner in the French Ministry of Research's 2008 business plan competition for innovative companies.
- /// Furthermore, InnaVirVax has obtained a grant-in-aid from the French National Research Agency as part of the BiotecS program on therapeutic HIV vaccines.
- /// InnaVirVax has completed a fundraising of €1.1 M in mid 2009.
- /// Non clinical toxicology studies have been completed for the new HIV-1 therapy.

COLLABORATIONS SOUGHT

InnaVirVax is seeking industrial partners (in the therapeutic and diagnostics sectors) with the ability to co-develop and to pursue the development of InnaVirVax's projects.

> 2 patents families from the INSERM and the Paris Public Hospitals Group (AP-HP) > 7 salaried staff

Strengths: developing the applications of a breakthrough innovation.

Innovation assets: the company's development products address unmet needs.



| Diagnostics |

IntegraGen



INTEGRAGEN

FIELD OF ACTIVITY

IntegraGen identifies genetic variants associated with polygenic diseases (autism, metabolic syndrome, obesity, diabetes and cancer) and developing diagnostic tools.

KEYWORDS

Autism - Metabolism - Diagnostics - Genetics - Oncology.

CEO Bernard Courtieu

Contact details Genopole Campus 1
5, rue Henri-Desbruères - F-91030 ÉVRY

Tel. +33 1 60 91 09 00

E-mail contact@integragen.com

Web site www.integragen.com

Date of founding 2000

BACKGROUND

IntegraGen was founded in 2000 on the basis of a locus identification technology for familial, polygenic diseases. The company rapidly built a portfolio of patents protecting its discoveries in the field of genetic predispositions..

DESCRIPTION OF THE PRODUCTS SERVICES/TECHNOLOGY

- IntegraGen offers pharmacogenomic services (sequencing and genotyping) to research organizations on a CRO basis.
- Diagnostics: IntegraGen is developing panels of biomarkers likely to indicate an increased risk of disease onset (in autism and oncology), contributing to early molecular diagnosis and treatment.

CUSTOMER REFERENCES COLLABORATIONS/HIGHLIGHTS

- Licence agreement with a CLIA laboratory in USA.
- Service contracts with Servier.
- Industrial and academic collaboration agreement for biomarkers validation in the field of oncology.

COLLABORATIONS SOUGHT

Pharmaceutical co-development in metabolic diseases (diabetes/obesity), oncology, autism and CNS diseases.

Annual turnover: €2,8 M > 24 patents > 24 salaried staff

Strengths: a full range of genetics platforms. Validated diagnostic tools.

Innovation assets: validated molecular diagnostic tools. IntegraGen's HIPTM technology.





| R&D services and products |

LPS BioSciences

FIELD OF ACTIVITY

Bacterial endotoxin production and analysis.
R&D in antigens and adjuvants.
Detection of bacterial pathogens.

KEYWORDS

Endotoxin - Lipopolysaccharide - Antigen -
Detection - Adjuvant - Vaccine.

Founder Martine Caroff

Contact details Équipe Endotoxines,
structures et activités

Bât. 409, IGM,

Université Paris-Sud - F-91405 ORSAY

Tel. +33 1 69 15 71 91 / +33 6 77 78 98 13

E-mail martine.caroff@gmail.com

Date of founding mid 2011

BACKGROUND

LPS-BioSciences is a spin-out from Paris-Sud University and CNRS. It combines an exclusive, proprietary technology for endotoxin production and characterization with the acknowledged, international expertise of its co-founder, Martine Caroff.

DESCRIPTION OF THE PRODUCTS SERVICES/TECHNOLOGY

LPS-BioSciences provides services for the production and characterization of endotoxins (lipopolysaccharides) and collaborative R&D projects with biotech companies and academic research labs.

Innovative customized endotoxin services are available, as well as novel concepts in the adjuvant/vaccine field.


CUSTOMER REFERENCES COLLABORATIONS/HIGHLIGHTS

- Development of a new, non-toxic method for endotoxin extraction (patent).
- Commercialization of endotoxin assay tools in 2012.
- A prize winner in the 2011 French national business plan competition for hi-tech start-ups.
- A prize winner in the 2008 French national business plan competition for hi-tech start-up.
- Winner of the 2006 research exploitation prize awarded by the Essonne County Council and Paris-Sud University.

COLLABORATIONS SOUGHT

Pharmaceutical companies involved in R&D on antigens and vaccines.

Biotech and diagnostics companies.



> 1 granted patent, 1 patent pending

Strengths: large-scale, on-demand LPS production. Acknowledged expertise in LPS characterization.

Innovation assets: methods for endotoxin extraction and purification (without the use of toxic solvents).



| Therapeutics |

LTKfarma



FIELD OF ACTIVITY

Development and marketing of cell therapy products (derived from modified T-cells) for the treatment of leukemia and of certain auto-immune diseases and solid tumors.

KEYWORDS

Cell Therapy - T lymphocyte - Suicide gene - GvHD - Allograft.

BACKGROUND

LTKfarma is a biotech start-up that was spun out of research performed at the "Biology and Therapy of Immune Diseases" laboratory (a joint CNRS/Pierre & Marie Curie University of Paris research unit) and the Biotherapy Division at the Pitié-Salpêtrière Hospital.

DESCRIPTION OF THE PRODUCTS SERVICES/ TECHNOLOGY

LTKfarma develops two products by modifying the donor's T lymphocytes *in vitro* via the introduction of a "suicide gene" (TK-1 and TK-54). This enables post-graft cell selection.

▀ Drastically reduce mortality from graft-versus-host disease (GVHD), the main complication of allogeneic, hematopoietic stem cell transplantation (HSCT), i.e. a target figure of 5% instead of today's 20%-60%.

▀ Offer HSCT as a therapeutic alternative with an enhanced risk/benefit ratio for patients suffering from solid tumors and severe forms of autoimmune diseases such as scleroderma, multiple sclerosis and rheumatoid arthritis.

CUSTOMER REFERENCES COLLABORATIONS/ HIGHLIGHTS

To date, TK-1 has been tested in Phase I/II clinical trials for the treatment of hematological cancers, with funding from the company's partners, the Paris

CEO Evence-Charles Coppée

COO Dorothée Carvallo

Pharmaceutical development and Regulatory

Director Patricia Noguez-Hellin

Scientific founders David Klatzmann,

François Lemoine, Dr José Cohen

Contact details Pépinière Genopole® Entreprises

4, rue Pierre-Fontaine - F-91058 ÉVRY Cedex

Tel. +33 6 08 97 78 51

E-mail contact@ltkfarma.fr

Web site www.ltkfarma.fr

Date of founding March 2006

Public Hospitals Group (AP-HP) and the French Muscular Dystrophy Association (AFM).

In parallel, LTKfarma is developing a new product TK-54 (derived from TK-1) and will start new Phase I/II clinical trials for leukemia in 2012.

LTKfarma obtained from EMA (European Medicines Agency) for TK54 product an ATMP classification (Advances Therapy medicinal Product) and an orphan drug designation in acute myeloid leukemia application respectively, in March and September 2010.

LTKfarma was a top prizewinner in the French Ministry of Research's 2005 business plan competition for innovative companies, obtaining a €450,000 grant-in-aid.

COLLABORATIONS SOUGHT


The company is currently seeking industrial and commercial partnerships for the development and commercialization of its TK-1 and TK54 products.

In parallel, the company has committed to finding financial partners which will enable it to pursue its regulatory and clinical efforts, with the goal of obtaining its first product marketing approval in 2016 with an extension in 2017.

> 31 patents in 6 different families > 3 salaried staff

Strengths: an experienced team and strong IP.

Innovation assets: the company's patented "suicide gene" technology.



| Therapeutics |

MAT Biopharma



FIELD OF ACTIVITY

MAT-Biopharma (Monoclonal Antibodies Therapeutics) is specialized in research and development of monoclonal antibodies for therapeutic and diagnostic use.

KEYWORDS

Monoclonal antibodies.

DESCRIPTION OF THE PRODUCTS SERVICES/TECHNOLOGY

Eight products in preclinical development:

- // Ophthalmology:
anti-CD160 with anti-angiogenic activity.
- // Oncology:
 - Anti-CD160 isoform transmembrane for NK lymphomas treatment.
 - Two bi-specific monoclonal antibodies (anti-CD5 / anti-CD32 and anti-CD5 / anti-HLADR).
- // Autoimmune disease:
anti-CD160 isoform transmembrane.
- // Infectious / nosocomial disease:
anti-aspergillus fumigatus for diagnostic use and treatment of invasive Aspergillums infections.

Clinical development:

- // MAT-Biopharma is developing an Yttrium-90-coupled polyclonal antiferritin antibody (Ferritarg-P) for the radioimmunotherapy of refractory Hodgkin's disease. Ferritarg-P obtained "Orphan Medicinal Product" status for this indication from EMA in 2004 and from FDA in 2006, and has successfully completed a Phase I/II clinical trial. The protocol for a pivotal Phase III trial (which should enable product marketing authorization) has been validated by EMA.
- // MAT-Biopharma has a chimeric gamma-1 antiferritin monoclonal antibody which, when coupled to Yttrium-90, should be developed for treating pancreatic and liver cancers.

CEO François Vallet

Contact details

Genopole Campus 1
5, rue Henri-Desbrùères - F-91030 ÉVRY CEDEX

Tel. +33 1 60 91 78 88

E-mail francois.vallet@matbiopharma.com

Web site www.matbiopharma.com


Date of founding 15/02/2000

COLLABORATIONS SOUGHT

On the basis of its double expertise in both antibodies and oncology, MATBiopharma proposes a set of services for academic and industrial laboratories, in the frame of its new "MAB'Solut" activity (www.mabsolut.com):

- // Antibody creation
 - Antigen preparation and modification (purification, hapten conjugates)
 - Immunisations, splenic fusions, screening, selection and production of hybridomas.
- // Production, purification and analytical testings (ELISA, flow cytometry, FPLC/SEC, denaturing and non denaturing electrophoresis gel).
- // Antibody engineering
 - Molecular biology for the development of optimized antibodies: chimerization, fragment design and production (ScFV, ScFV2, dAb), bispecific antibodies.
 - Chemical fragmentation (Fab, Fab'2) and antibody labelling.
- // Antibody validation and *in vitro* / *in vivo* characterization
 - Development of bioassays for mechanisms of action studies of antibodies.
 - *In vivo* efficacy studies in rodent models, development at request of *in vivo* specific models.

> 6 patents > 9 employees



| Therapeutics |

Metabrain Research



FIELD OF ACTIVITY

Metabrain is a Partnering Research Organization (PRO) that enriches and leverages early-stage pipelines in the field of metabolic and neurodegenerative diseases. Its customers include pharmaceutical, biotech and food industry companies and academic labs.

KEYWORDS

Drug and nutraceutical discovery - Lead Optimization - Metabolism - Diabetes - Obesity - Alzheimer - Collaborative innovation.

CEO Valérie Autier

Contact details 4, avenue du Président

François-Mitterrand - F-91380 CHILLY-MAZARIN

Tel. +33 1 69 19 41 50

E-mail contact@metabrainresearch.com

Web site www.metabrainresearch.com

Date of founding March 2009

BACKGROUND

A group of 30 scientists - all experts in diabetes and metabolic disorders - joined Metabrain Research on the basis of their know-how in drug discovery developed at Merck Serono.

DESCRIPTION OF THE PRODUCTS SERVICES/TECHNOLOGY

Metabrain runs collaborative research projects and contract research programs that focus on the links between metabolic and neurodegenerative diseases. We are investigating both therapeutic (drug-based) and preventive (nutraceutical) approaches in the treatment of diabetes, obesity and Alzheimer's disease.

CUSTOMER REFERENCES COLLABORATIONS/HIGHLIGHTS

- /// Customers and partners: 7 biotech companies and 3 big pharmas.
- /// 4 national and European Union collaborative programs are ongoing or under review.
- /// Work on NCEs, NBEs, natural products and food supplements.

COLLABORATIONS SOUGHT

- /// Research alliances on first-in-class antidiabetic drugs.
- /// Contract research: medicinal chemistry and *in vitro* and *in vivo* biological profiling.
- /// Research collaborations for validating novel targets and discovering new drugs on the basis of connections between metabolic and CNS disorders.

Annual turnover: € 3 M > 30 salaried staff

Strengths: turnkey collaborative research programs. Standard drug discovery platform that specializes in metabolic disorders.

Innovation assets: common molecular targets for treating both metabolic and neurodegenerative disorders.



| R&D services and products |

MilleGen



FIELD OF ACTIVITY

Selection (from human libraries) and engineering of human, murine and other monoclonal antibodies.

DNA sequencing, molecular biology projects, peptide synthesis and immunization services.

KEYWORDS

Antibody libraries - Library screening - Antibody affinity improvement - DNA sequencing - Molecular biology projects - Peptide synthesis - Immunization.

BACKGROUND

MilleGen was created in 1999 by Dr Hakim Kharrat and Dr Khalil Bouayadi. It was a prizewinner in the French Ministry of Research's business plan competition for innovative companies in 1999 (in the "emerging projects" category) and 2000 (in the "creation and development" category).

The company then expanded by offering genomic and peptide synthesis services, in order to finance its in-house R&D activity in the field of directed molecular evolution and recombinant human antibodies.

DESCRIPTION OF THE PRODUCTS SERVICES/TECHNOLOGY

/// R&D on recombinant human antibodies for therapeutic and diagnostic purposes: a random mutagenesis technology (MutaGen™) for the improvement of immunological and pharmacological properties of human or non-human antibodies; MutaBank™ human recombinant antibody libraries for screening against a target of interest.

CEO Hakim Kharrat

Contact details Immeuble BIOSTEP - Bât. A

Rue Pierre et Marie Curie

BP 38183 - F-31681 LABEGE Cedex

Tel. +33 5 61 28 70 10

E-mail contact@millegen.com

Web site www.millegen.com

Date of founding October 1999

/// A broad range of custom services in genomics (DNA sequencing, cloning, gene synthesis, directed mutagenesis...), custom peptide synthesis and immunization services.

CUSTOMER REFERENCES COLLABORATIONS/HIGHLIGHTS

After several years dedicated to the development of patented technologies (such as MutaGen™ for antibody improvement or the production of hyperdiverse libraries of recombinant antibodies), MilleGen has established a platform for selecting recombinant human antibodies and optimizing them for entry into preclinical development. MilleGen is working on therapeutic antibodies with public- and private-sector partners.

COLLABORATIONS SOUGHT

/// The antibody platform is targeted at pharmaceutical companies, biotech firms and academic research groups developing therapeutic antibodies.


/// Services for public and private laboratories.

Annual turnover: €1 500 K > 5 patents > 25 salaried staff

Strengths: robustly patented technologies and molecules. Highly competent team of scientists with in-depth know-how in the field of recombinant antibodies and directed evolution.

More than ten years of know-how in DNA sequencing and peptide synthesis, customer focus.

Innovation assets: MutaGen technology and hyperdiverse antibody banks.



| R&D services and products |

New England Biolabs France



FIELD OF ACTIVITY

New England Biolabs is a private company manufacturing reagents for the life science industry particularly focused on products for genomic research.

KEYWORDS

Enzymes - Molecular Biology - Sequencing kits - Molecular weight ladders - Epigenetic - Genomic Research.

General manager France Jean-Frédéric Loubereau

Contact details Genopole Campus 1

Genavenir 8 - Aile D - 5, rue Henri-Desbruères

F-91030 ÉVRY Cedex

Tel. +33 1 69 90 87 15

E-mail info@fr.neb.com

Web site www.neb-online.fr

Date of founding 02/03/2011

BACKGROUND

Established in the mid-1970s as a co-operative laboratory of experienced scientists, New England Biolabs (NEB) is a world leader in the production and supply of reagents for the life science industry. NEB is headquartered in Ipswich, Massachusetts, U.S.A and has six subsidiary offices including NEB France which was opened in May 2011.

DESCRIPTION OF THE PRODUCTS SERVICES/ TECHNOLOGY

NEB now offers the largest selection of recombinant and native enzymes for genomic research and continues to expand its product offerings into areas related to nucleic acid manipulation, epigenetics and protein expression. NEB serves the academic and industrial research market in addition to customised products for drug discovery and molecular diagnostics.

Strengths: NEB is vigorously committed to servicing our customers with best-in-class products, unparalleled technical support and an R&D depth unmatched by organisations many times our size.



| Therapeutics |

Nokad

NOKAD



FIELD OF ACTIVITY

Validation of *in vivo* targets.

KEYWORDS

Thrombosis biomarkers - Therapeutic and preventive vaccines - Functional protein knock-out (KO) - Treatment of thrombopenia - Bioinformatics platform - Rapid validation of *in vivo* targets in various species.

BACKGROUND

Nokad was founded in 2004 with the objective of developing an innovative technology platform for the *in vivo* validation of drug targets. This development work prompted Nokad to explore a newly discovered biological pathway in hematopoiesis and, in parallel, validate its vaccine approach in several in-house and external collaborative programs.

DESCRIPTION OF THE PRODUCTS SERVICES/TECHNOLOGY

- // Viable adult Erythropoietin-functional Knock-Out mice and rats.
- // New strategies in therapeutic and prophylactic vaccination using the cross-reactivity approach.
- // Functional protein KO in various mammalian species.
- // *In vivo* validation of hepatic or local targets via RNAi or shRNA delivered by a recombinant virus.
- // *In vivo* overexpression of target genes using recombinant adenoviruses or adeno-associated viruses.
- // Generation of antibodies against non-antigenic or conserved proteins using the cross-reactivity strategy 3.

CEO Amine M. Abina

Vice-président François Erard

Contact details Pépinière Genopole® Entreprises
4, rue Pierre-Fontaine - F-91058 ÉVRY Cedex

Tel. +33 1 60 87 89 90

E-mail contact@nokad-pharma.com

Web site www.nokad-technology.com

Date of founding 21/01/2004

CUSTOMER REFERENCES COLLABORATIONS/HIGHLIGHTS

- // Creation of the first viable EPO-KO models in several animal species.
- // Discovery of a new biological pathway in hematopoiesis, in collaboration with the INSERM.
- // *In vivo* target validation programs performed for pharmaceutical companies.
- // Receipt of a major grant from the French National Research Agency in 2009.

COLLABORATIONS SOUGHT

We are looking for partners involved in the development of biomarkers of venous and arterial thrombosis and the treatment of thrombocytopenia.

Collaborations are also sought for the evaluation of new strategies in therapeutic and prophylactic vaccination in human and veterinary medicine.

Nokad is also looking for a partner to distribute some of the animal models developed in-house.

Innovative therapeutics applied to various types of cancer; therapeutic vaccination.

> 5 patents > 6 salaried staff

Strengths: an innovative strategy for target validation and for vaccination.
Rapidly available, high-quality information on validation.

Innovation assets: an integrated platform for *in vivo* target validation; a novel vaccine strategy.



| Medical devices |

Novacyt



FIELD OF ACTIVITY

NOVACYT develops innovative medical cytology solutions (notably an entirely automated, liquid-based cytology system) which are sold worldwide.

KEYWORDS

In vitro diagnostics - Automation - Liquid-based cytology.

CEO Éric Peltier

Operations director Jean-Pierre Crinelli

Contact details Immeuble Le Nungesser

13, avenue Morane-Saulnier

F-78140 VÉLIZY-VILLACOUBLAY

Tel. +33 1 39 46 51 04

E-mail info@novacyt.com

Web site www.novacyt.com

Date of founding 11/07/2006

BACKGROUND

NOVACYT was founded with the goal of becoming a major player in cytology diagnostics. The company's expertise know-how is based on its knowledge of medical cytology and the development, industrialization and commercialization of *in vitro* diagnostic devices.

DESCRIPTION OF THE PRODUCTS SERVICES/TECHNOLOGY

NOVACYT commercializes a complete thin-layer cytology range. The NOVAPREP® Vial Test Gyn and Non Gyn consumables and the NOVAPREP® Decantation System are dedicated for use with the NOVAPREP® NPS25 and NPS50 processing systems. NOVACYT sells its automated cytology solutions in France and has a worldwide distribution network.

CUSTOMER REFERENCES COLLABORATIONS/HIGHLIGHTS

In just two years, NOVACYT has developed and commercialized a fully automated solution for liquid-based cytology, which has already been adopted in over 15 countries. Thanks to its standardization and high quality, this innovative system is improving diagnostic performance levels in medical cytology.

COLLABORATIONS SOUGHT

NOVACYT is looking for commercial partners in Brazil, China and India.



Annual turnover: €1,5 M > 19 patents > 7 salaried staff

Strengths: innovation, industrial processes, marketing & sales, regulatory issues. Market knowledge, product-market matching and a multidisciplinary team.



| Therapeutics |

Novagali Pharma

NOVAGALI
PHARMA



FIELD OF ACTIVITY

Novagali Pharma is a French ophthalmic pharmaceutical company that develops and markets innovative ophthalmic products for all segments of the eye. Thanks to its three proprietary technology platforms, the company has a portfolio of innovative products from which one is already commercialized and two are in phase III clinical trials.

KEYWORDS

Ophthalmology - Technologies - Cationorm®

President of the board Jérôme Martinez

Contact details 1, rue Pierre-Fontaine

Genavenir 4 – F-91058 ÉVRY Cedex

Tel. +33 1 69 87 40 20

Fax +33 1 69 87 40 30

E-mail contact@novagali.com

Web site www.novagali.com

Date of founding 08/08/2000

BACKGROUND

Novagali Pharma was created in August 2000 by Simon Benita. The company then set up its labs and corporate offices at the Évry Genopole®. In 2003, the company started to focus on ophthalmology and launched its first product Cationorm® in France in 2008.

DESCRIPTION OF THE PRODUCTS SERVICES/TECHNOLOGY

Based on its three patented technology platforms, Novasorb®, Eyeject® and Li-prodrug®, Novagali has developed a portfolio of diversified products in late-stage development. Cationorm®, indicated to treat dry eye symptoms, is the first product marketed in Europe, South East Asia and MENA.

Products under development include Cyclokot® (phase III) for the treatment of severe dry eye syndrome, Vekacia® (phase III) for treatment of

vernal keratoconjunctivitis, Catioprost® (phase II) indicated for the treatment of glaucoma and Cortiject® (Phase I) for the treatment of diabetic retinopathies.

CUSTOMER REFERENCES COLLABORATIONS/HIGHLIGHTS

Since its incorporation, Novagali Pharma has raised a total of around €59 M in four rounds of fundraising.


In 2008, Novagali Pharma launched the first product to come out of its pipeline: Cationorm®, an innovative cationic emulsion for treating the symptoms of dry eye syndrome.

In April 2010, Novagali Pharma and its partners in the Vitrena project obtained €9.4 M in funding from Oséo for this diabetic retinopathy project. In July, Novagali Pharma successfully achieved an IPO raising €22M and is listed on NYSE Euronext Paris - Compartment C - ISIN: FR0010915553 - MNEMO: NOVA.

> 28 patents > 44 salaried staff

Strengths: Cationorm®, its first product on the market; 3 innovative technology platforms, with Novasorb® for the eye surface and the anterior segment, Eyeject® for administering drugs to the back of the eye and Li-Prodrug® based on prodrug administration to the eye; a late stage pipeline with two products in Phase III; a pilot production unit for industrial-scale transfers. Novagali Pharma is an integrated company combining experience in and knowledge of formulation, analysis, preclinical testing, manufacturing, clinical trials, regulatory affairs and marketing.

Innovation assets: development of innovative drugs for all segments of the eye; patented technologies to increase the bioavailability of drugs while improving tolerance.



| Therapeutics |

Nutrivercell



FIELD OF ACTIVITY

Nutrivercell designs, formulates, develops, manufactures and markets innovative nutritional solutions with medical added value.

KEYWORDS

Nutritional ingredients - Polyphenols - Combination with medicines - Infectious diseases - Inflammation.

BACKGROUND

Nutrivercell was founded in March 2009 by a pharmacist with the objective to reinforce conventional medicines efficiently with high quality nutritional ingredients.

DESCRIPTION OF THE PRODUCTS SERVICES/TECHNOLOGY

- // Nutrivercell has focused its development on infectious disease and inflammation.
- // Duab®, a Dual Antibacterial product, is used in combination with antibiotics to strengthen their efficacy by reducing the virulence and the resistance of the main bacterial strains met in the urinary tract infections. DUAB® was launched in French pharmacies at the end of 2010 and is also being promoted to specialist physicians, gynecologists and urologists by medical sales representatives.

CUSTOMER REFERENCES COLLABORATIONS/HIGHLIGHTS

- // By July 2011, over 1 500 pharmacies were selling DUAB® over the counter.
- // Launch of the anti-inflammatory program in partnership with the University of Bordeaux.
- // The company's first international collaboration.

CEO Loïc Renard
International Project Manager Cynthia Renard
Contact details Pépinière Genopole® Entreprises
 4, rue Pierre-Fontaine - F-91058 ÉVRY Cedex
Tel. +33 1 45 06 69 56
E-mails loic.renard@nutrivercell.com
 cynthia.renard@nutrivercell.com
Web site www.nutrivercell.com
Date of founding 31/03/2009

COLLABORATIONS SOUGHT

- // Foreign manufacturers or distributors specializing in urology and gynecology, with a view to developing international markets.



> 3 patents > 2 salaried staff

Strengths: innovative strategy focused on combination with drugs. Strong scientific, medical and supply chain expertise.
Innovation assets: synergistic nutraceutical-drug combinations.



| Therapeutics |

ObeTherapy Biotechnology



FIELD OF ACTIVITY

Drug discovery for the treatment of obesity and metabolic diseases.

KEYWORDS

Obesity - Type II diabetes - Lean or starvation phenotype.

BACKGROUND

ObeTherapy Biotechnology's business is based on its innovative approach to identifying novel genes that can be used as therapeutic targets in obesity. The paradigm is diametrically opposed to conventional ethos in this field: instead of looking at what genetically characterizes the obese phenotype, ObeTherapy Biotechnology is focusing on the lean or starvation phenotype.

DESCRIPTION OF THE PRODUCTS SERVICES/TECHNOLOGY

ObeTherapy Biotechnology's main goals are to:

- // identify new target genes for the treatment of obesity and related pathologies,
- // validate these targets by establishing transgenic animal models,
- // identify new chemical entities which can modulate the products of these target genes,
- // develop these NCEs up to the preclinical phase.

This has enabled it to identify, validate and patent a family of genes involved in energy supply. These genes are high potential therapeutic targets, since they are non-redundant and are very specific. Drugs that bind to these targets are identified by using a high-throughput screening method patented by ObeTherapy.

CEO Itzik Harosh

Contact details Pépinière Genopole® Entreprises
4, rue Pierre-Fontaine - F-91058 ÉVRY Cedex

Tel. +33 1 60 87 89 04

E-mail iharosh@obetherapy.com

Web site www.obetherapy.com

Date of founding 19/01/2000

CUSTOMER REFERENCES COLLABORATIONS/HIGHLIGHTS

The discovery of new therapeutic molecules and their development up to market launch are performed in close collaboration with the Zambon group (Milan, Italy). In parallel, a new gene candidate and inhibitors have also been recently identified. The establishment of an alliance for this second target is currently under discussion.

COLLABORATIONS SOUGHT

ObeTherapy Biotechnology is currently seeking industrial and financial alliances, in order to finalize the preclinical trials on two lead targets.

> 5 patents > 2 salaried staff

Strengths: one molecule in the preclinical phase and another in "lead optimization".

Innovation assets: ObeTherapy looks at targets produced in a lean phenotype.



FIELD OF ACTIVITY

Oxalya is a numerical simulation access facilitator. Oxalya's expertise covers a wide range of activities: the editing of Computing and Visualization infrastructures management software, Infrastructures provisioning, and an On demand computing service.

KEYWORDS

High-performance computing (HPC) -
Numerical simulation - Visualization -
Computing solutions deployment -
On demand HPC (service).

BACKGROUND

Building on several years of experience as a HPC infrastructures provider on the European market, Oxalya stands out for its important Research & Development investments. Since 2006, Oxalya participates in and/or coordinates numerous national or international collaborative R&D programs. These programs play an important innovation catalyst role. In this way, Oxalya has been able to adapt to its environment needs : propose a simple, automated and secured access to numerical simulation.

Oxalya has developed two key software for the management of remote Computing and Visualization infrastructures : VirtualNodes® and VisuPortal®. These two solutions provide users with a new HPC experience : an easy, fast and secured access to computing or visualization resources.

DESCRIPTION OF THE PRODUCTS SERVICES/TECHNOLOGY

VirtualNodes® : through a single secured Web portal, access a mutualized data center remotely, and under a 'pay as you go' scheme. VirtualNodes® is fully automated, enabling you to access computing resources whenever you need, as if they were your own (resources). Via a simple Web browser, take advantage of a comprehensive computing environment, notably equipped with a job scheduler, permanent storage capacity, remote infrastructures management software and a system to help you deploy your own tools on the solution.

CEO Alban Schmutz

Contact details 18-20, rue Pasteur

F-94270 LE KREMLIN-BICÈTRE

Tel. +33 1 49 58 45 70

Fax +33 1 45 59 02 51

E-mail info@oxalya.com

Web site www.oxalya.com

Date of founding May 2003

VisuPortal® : solution for remote collaborative visualization, VisuPortal® enables you to easily manage and optimize your visualization equipments. Deployed in your own infrastructures, VisuPortal® gives you access to collaborative work, remote post-processing, the control of your visualization screens (equipments) and even enables you to benefit from interactive computing sessions with your own tools available in a SaaS mode.

CUSTOMER REFERENCES COLLABORATIONS/HIGHLIGHTS

Oxalya contributes to a number of major collaborative R&D projects, all aiming to enable researchers and engineers to focus on their core research and developments *via* the use of collaborative and easy-access interoperable solutions.

Among other projects, Oxalya leads the Collaviz consortium ('ANR' project with 28 partners), which objective is to develop a remote collaborative framework for scientific visualization purposes.



| R&D services and products |

PartnerChip



FIELD OF ACTIVITY

PartnerChip offers its customers a panel of tools for genomics, high-density microarray analysis, diagnostics and bioinformatics.

KEYWORDS

Biomedicine - Microarray - Diagnostics - Genomics - Bioinformatics.

CEO Pascal Soularue

Director Nadia Billault

Contact details Bât. G2

2, rue Gaston-Crémieux - F-91000 ÉVRY

Tel. +33 1 60 87 34 62

+33 1 60 87 34 73

E-mails pascal.soularue@partnerchip.fr

pascal.soularue@cea.fr

nadia.billault@cea.fr

Web site www.partnerchip.com

Date of founding 25/01/2005

BACKGROUND

PartnerChip was incorporated in January 2005 and is an accredited "Affymetrix Official Service Provider". Since 2007, PartnerChip has been developing its own diagnostic microarrays. In 2010, PartnerChip became official service provider for Roche-Nimblegen.

DESCRIPTION OF THE PRODUCTS SERVICES/TECHNOLOGY

PartnerChip offers services such as array design, spotting quality control, targeted on-chip hybridization on chips (gene expression, exon jumping analysis, genotyping, resequencing, comparative genomic hybridization, microRNAs, etc.), array preparation and reading, generation and analysis of raw data (normalization, comparison, statistical analysis, clustering, pathway involvement and data mining).

PartnerChip also develops resequencing chips for diagnostics and antibodies arrays.

CUSTOMER REFERENCES COLLABORATIONS/HIGHLIGHTS

PartnerChip was involved in the Medicen Paris Region cluster's Biotype project and in five European Union projects (EuroIron, ProteinStorage, PrediCancer, NMD-Chip, CaroMaize).

COLLABORATIONS SOUGHT

PartnerChip is seeking to establish collaborations with all types of biotech firms (red, green and white), pharmaceutical companies and CROs.



Annual turnover: € 300 K > 5 salaried staff

Strengths: responsiveness, creativity, 20 years of experience in genomics.

Innovation assets: the development of new tools in the field of diagnostics.



| R&D services and products |

PhenoPups

PhenoPups

PRECLINICAL PAEDIATRIC SERVICES

FIELD OF ACTIVITY

PhenoPups is a new innovative, preclinical services company, spin-off of the French National Institute of Health and Medical Research (INSERM). PhenoPups has developed a novel phenotyping platform for newborn and juvenile rodents.

KEYWORDS

Pediatric drugs - Non-invasive - Animal models - Phenotyping - Preclinical - Rodents.

Chairman & CEO Christian Milla

COO Estelle Durand

Advisors Jorge Gallego (Dr INSERM)

Boris Matrot (Ingineer INSERM)

Contact details Siège PhenoPups

Pépinière Genopole® Entreprises

4, rue Pierre-Fontaine - F-91058 ÉVRY CEDEX

Centre de recherche PhenoPups

Hôpital Robert-Debré - 48, bd Sérurier - F-75019 PARIS

Tel. CM +33 6 43 74 10 65

ED +33 6 30 60 23 44

E-mail contact@phenopups.com

Web site www.phenopups.com

Date of founding April 2010

BACKGROUND

PhenoPups was born from a fruitful collaboration between engineers, developmental biologists and clinicians at Robert Debré Paediatric Hospital. This collaboration was centered on a strategic objective: to improve the development of paediatric compounds. From that point, a novel technology platform and methodology is now available which allows to develop and characterize relevant and predictive paediatric animal models.

DESCRIPTION OF THE PRODUCTS SERVICES/TECHNOLOGY

The PhenoPups platform allows high-throughput screening tests able to characterize genetically engineered rodent models at different stages of postnatal development. Proprietary protocols have been designed to characterize vital functions (cardiorespiratory control, thermoregulation, arousal...) as well as psychomotor and cognitive development. PhenoPups supplies a comprehensive *in vivo* screening methodology for new candidate drugs and paediatric indications.

CUSTOMER REFERENCES COLLABORATIONS/HIGHLIGHTS

PhenoPups was considered by Trophos as the only technology platform to offer an innovative phenotyping service for genetically modified mouse pups. Trophos is a leading French Biotech company specializing in CNS. Our pediatric drug testing platform is now being used in the frame of the European Union FP7 TINN project.

COLLABORATIONS SOUGHT

We are looking for partners for collaborative projects in the field of pediatric drug development.

> 1 patent

Strengths: an exclusive innovative services platform performing "high-through-put" phenotyping of newborn and juvenile rodents. Exclusive know-how and standardized methodologies adapted to newborn and juvenile rodent investigation. Recognized expertise in drug development and Paediatric Research from Management and Founders.



| R&D services and products |

PhInC Development



FIELD OF ACTIVITY

Methodological and scientific support for biotech firms and small labs for preclinical development and Phase I and IIa clinical development.

KEYWORDS

Early-stage development (preclinicals, Phase I & IIa clinical trials) - Analysis of exploratory data and PK and PD results - Pharmacometrics.

CEO - Co-founders **Bernard Orlandini,**

Virginie Gualano, Mathieu Felices

Contact details 5, rue Henri-Desbrùères

Immeuble Genavenir 8 - F-91030 ÉVRY Cedex

Tel. +33 1 60 87 14 79

Fax +33 1 60 87 14 75

E-mail bernard.orlandini@phinc.fr

Web site www.phinc.fr

Date of founding 23/10/2008

BACKGROUND

PhInC was incorporated by 4 experienced CRO/ pharmaceutical professionals with complementary skills (pharmacology, biostatistics, pharmacokinetics, biomedical research and clinical development).

DESCRIPTION OF THE PRODUCTS SERVICES/TECHNOLOGY

Our modus operandi is completely designed in the context of your development program, and remains flexible while ensuring a constant support over time.

Based on an integrated and multidisciplinary approach, PhInC brings an adapted support to preclinical and early clinical development, on the three following areas:

/// Scientific and methodological advice, from the preclinical phases through to first-in-man trials and proof-of-concept in the patient. As a natural extension of this approach, PhInC can evaluate the corresponding resources and operational costs (partners, investments, infrastructure, timelines, etc.).

/// Trial design and coordination of study set-up. This step also includes constitution of a regulatory and scientific documentation,

as well as selection and monitoring of the most appropriate subcontractors (CROs and academic labs).

/// Expert analysis to maximize product's potential at each development phase: lead optimization and transposition to man with physiology-based pharmacokinetic approach, validation of biomarkers and target doses, determination of dose-response models using biostatistical approaches, PK/PD modeling, population analyses and meta-analyses.

CUSTOMER REFERENCES COLLABORATIONS/HIGHLIGHTS

/// Consolidation of the number of our clients in Europe.

/// Reflection on the implementation of a new collaborative platform in research and development.

COLLABORATIONS SOUGHT

Exploratory analyses with biotech firms, small pharma companies and multinationals. Co-development of new methods or protocols in the field of clinical development.

> 7 salaried staff

Strengths: optimization of early-phase development costs and timelines by applying an upstream, made-to-measure approach for small pharma companies. Enabling them to keep control of their development and independence when faced with the large CROs. By creating a development plan designed to fit the new drug and powered by an extensive data analysis, the results of your early development can generate high added-value information and thus can emphasize the interest for the drug under development.



Physikron



FIELD OF ACTIVITY

Development of new mass spectrometry solutions.

KEYWORDS

Tandem mass spectrometry -
High-throughput - Low sample requirement -
Proteomics

Chairman and CEO David Znaty

Vice-president Patrick Vayn

CSO David Scigocki

Contact details Pépinière Genopole® Entreprises

4, rue Pierre-Fontaine - F-91058 ÉVRY Cedex

Tel. +33 1 60 87 89 87

Fax +33 1 60 87 89 99

E-mail patrick.vayn@physikron.com

Web site www.physikron.com

Date of founding 22/06/2005

BACKGROUND

Physikron has developed analytical processes for tandem mass spectrometry (MS-MS) based on concepts from particle physics.

DESCRIPTION OF THE PRODUCTS SERVICES/TECHNOLOGY

These processes simultaneously produce several well-separated MS-MS spectra (with no selection of the individual primary mass) from a single MS-MS spectrum containing all the fragments of several different primary masses.

Machines equipped with the Physikron technology can significantly increase their acquisition throughput and decrease their sample requirement in MS-MS mode without hardware modification.

A higher acquisition throughput is particularly significant for liquid chromatography-coupled systems (LC MS-MS) because existing machines are only able to produce a part of the MS-MS spectra for the different primary masses going through the chromatography line. The system has notable uses in proteomics and medical diagnostics.

CUSTOMER REFERENCES COLLABORATIONS/HIGHLIGHTS

Collaboration with an academic laboratory. The technology has been validated by a big pharma.

COLLABORATIONS SOUGHT

Physikron is looking for co-development and/or licensing partners (mass spectrometers manufacturers, players in medical diagnostics).

> 3 patents > 2 salaried staff

Strengths: rapidity, analysis of complex mixtures and sample consumption strongly reduced.



| R&D services and products |



Polytheragene

FIELD OF ACTIVITY

Manufacture and sale of new high performance transfecting agents for gene therapy, high throughput screening and biomanufacturing.

KEYWORDS

Transfection - Gene therapy -
Biomanufacturing - Therapeutic proteins -
Vaccine.

CEO Pr Hervé Cheradame

Contact details LAMBE,

University Évry-Val d'Essonne

Bd François-Mitterrand - F-91025 ÉVRY cedex

Tel. +33 1 69 47 77 25

E-mail herve.cheradame@univ-evry.fr

Date of founding 2011



BACKGROUND

The association of two complementary teams from the MPI/LAMBE laboratories at the University of Évry and the "Centre de biophysique moléculaire" at Orléans led to the development of two patented polymer families for nucleic acid transfection.

DESCRIPTION OF THE PRODUCTS SERVICES/TECHNOLOGY


Two families of synthetic transfecting agents have been developed. The first is derived from polyethyle-nimine and the second is formed by amphiphilic tribloc copolymers for *in vitro* and *in vivo* applications. These compounds offer better efficacy and lower toxicity than market references.

CUSTOMER REFERENCES COLLABORATIONS/HIGHLIGHTS

- ✓ New formulas are currently under development at the MPI lab.
- ✓ Negotiations are taking place with biomanufacturers for tests.

COLLABORATIONS SOUGHT

We are looking for partnerships and co-development opportunities with biomanufacturers, companies offering high throughput cell screening and biotechnology laboratories developing DNA or RNA vaccines.



> 2 exclusive licences from the University Évry-Val d'Essonne (UEVE)

Strengths: high performance synthetic vectors. Complementary teams in chemistry and biochemistry.

Innovation assets: ability to develop high efficacy transfecting agents for specific applications (stem cells and cell suspension cultures).



SEBIA



sebia

FIELD OF ACTIVITY

Design, production and commercialization of *in vitro* diagnostic systems (instruments and reagents) for medical biology laboratories.

KEYWORDS

In vitro diagnostics - Clinical biochemistry - Electrophoresis - Instruments - Reagents - Monoclonal gammopathies - Hemoglobinopathies - Diabetes.

CEO Benoît Adelus

Contact details Parc technologique Léonard-de-Vinci

CP8010 Lisses - F-91008 ÉVRY Cedex

Tel. +33 1 69 89 80 80

E-mail sebia@sebia.com

Web site www.sebia.com

Date of founding October 1967

BACKGROUND

Since its incorporation forty years ago, SEBIA has become a global leader of innovative electrophoretic *in vitro* diagnostic systems and particular in capillary electrophoresis.

DESCRIPTION OF THE PRODUCTS SERVICES/TECHNOLOGY

Electrophoresis consists in the use of an electrical field to separate the proteins contained in biological samples. The most recent capillary electrophoresis technique is applied in the dedicated automated systems: CAPILLARYS™ range (CAPILLARYS™ 2, CAPILLARYS™ 2 Flex Piercing and CAPILLARYS™ 2 Neonat Fast) and MINICAP™.

The HYDRASYS™ range (with more automation in version 2), utilizes an agarose gel as support. The electrophoresis technique is a leading technology in the diagnosis of immune system diseases, myeloma, hemoglobin abnormalities, HbA1c and the detection of other protein markers.

CUSTOMER REFERENCES COLLABORATIONS/HIGHLIGHTS

SEBIA's R&D efforts are delivering results in two fields:

▮ The development of semi-automated or fully automated high-throughput systems, plus a full range of applications: proteins, lipoproteins, hemoglobin, HbA1c. SEBIA has recently launched two new automated instruments designed to the screening of Hemoglobinopathies (CAPILLARYS™ 2 Flex Piercing and CAPILLARYS™ Neonat Fast) as well as a new sampler for its agarose range (ASSIST).

▮ Via its eight subsidiaries and a network of 90 distributors, SEBIA offers an incomparable level of service worldwide.

COLLABORATIONS SOUGHT

SEBIA maintains close links with the medical community, including university labs associated with its research work and disease specialists developing applications.

SEBIA has also started a collaboration with the IMF (International Myeloma Foundation) who supports research projects and offers information and support to the patients suffering from myeloma and to their family.

Annual turnover: €120 M > 400 salaried staff

Strengths: the world number 1 in electrophoresis technology. Strong innovation capacity. A leader in the diagnosis of monoclonal gammopathies. High-level scientific and technical support.



| R&D services and products |

Sigma-Aldrich France

SIGMA-ALDRICH™

FIELD OF ACTIVITY

Sigma-Aldrich develops, produces and commercializes chemical and biochemical reagents for scientific research and analysis, R&D and production.

The Sigma-Aldrich site in Évry specializes in the custom synthesis of oligonucleotides intended for genomics, pharmaceutical research and the diagnostics industry.

KEYWORDS

Oligonucleotides - Primers - siRNA - Probes - qPCR - Oligos.

BACKGROUND

Oligonucleotide production started on Sigma Aldrich France's Évry site in 2005, following the acquisition of Prologo. For nearly 20 years, Sigma Aldrich's international oligonucleotide business has grown steadily and the company now has ten strategically located production sites worldwide (USA, Canada, Singapore, Australia, Japan, etc.).

DESCRIPTION OF THE PRODUCTS SERVICES/TECHNOLOGY

Thanks to its production and R&D site in Évry, Sigma Aldrich is able to offer researchers (in France and worldwide) high-quality oligonucleotides with very short timelines, thanks to its high-throughput automated synthesis platform. Sigma Aldrich's acknowledged know-how in the synthesis of DNA, siRNA, quantitative PCR probes and modified oligonucleotides means that the company can provide optimal solutions for genomics, pharmaceutical research and diagnostics.

Director/Manager Philippe Durival

Operations manager Évry Jean Chabbert

Contact details Genopole Campus 1
5, rue Henri-Desbrùères - F-91030 ÉVRY

Tel. +33 1 60 87 59 00

Fax +33 1 60 87 59 09

E-mail jean.chabbert@sial.com

Web site www.sigma-aldrich.com

Date of founding 08/03/2002

CUSTOMER REFERENCES

COLLABORATIONS/HIGHLIGHTS

Sigma Aldrich France's R&D teams have been involved in more than 50 scientific collaborations over the last three years. More than 20 scientific articles have been published and several patent applications have been filed as a result of these collaborations. The acquisition of strategic licenses [such as that from MIT, related to the production of siRNA] has enabled Sigma Aldrich France to position itself in the biotech field and thus complement Sigma Aldrich's general product range.


COLLABORATIONS SOUGHT

Sigma Aldrich France is developing collaborations in genomics, functional genomics and all related applications. In 2008, the company made several investments in medium-scale (mg) production of oligonucleotide, in order to broaden out the product range into the diagnostics sector.

> 6 patents > 50 salaried staff

Strengths: a large range of high-quality products and services.
Technology, expertise and innovation.

Innovation assets: custom development of new products and solutions.



| Therapeutics |

Sphergen

FIELD OF ACTIVITY

Sphergen is elaborating an innovative process for non-viral gene transfer called "electrotransfer"; this enables the delivery of veterinary drugs for the treatment of currently incurable diseases.

KEYWORDS

Non-viral gene therapy – Delivery of active compounds.

Manager Yves Scherman

Contact details Pépinière Genopole® Entreprises

4, rue Pierre-Fontaine - F-91058 ÉVRY Cedex

Tel. +33 6 07 96 09 09

Date of founding 01/07/2004

BACKGROUND

The technology is derived from work performed by Yves Scherman, the company's founder and manager.

DESCRIPTION OF THE PRODUCTS SERVICES/TECHNOLOGY

Sphergen's technology could be used for target validation purposes and the development of biomolecules by R&D departments in major pharmaceutical companies.

CUSTOMER REFERENCES COLLABORATIONS/HIGHLIGHTS

In addition, Sphergen collaborates to proof-of-concepts studies concerning the production by genetic immunization of antisera with antitoxin or antiviral activity for passive immunization therapy.

COLLABORATIONS SOUGHT

R&D collaborations (delivery, anti-serum development, target validation, etc.) with academic or industrial pharma/biotech partners.



Strengths: a proprietary electrotransfer platform.



Statlife



FIELD OF ACTIVITY

Statlife develops software for quantified evaluation of the benefits and risks associated with changes in drug regimens or in behavior (food habits, smoking, etc.), with a view to better prevention of today's major diseases.

KEYWORDS

Prevention - Prediction - Patient medical records - Risk scores - Epidemiological statistics.

BACKGROUND

Statlife was spun out from research work on disease risk prediction carried out at the Pierre & Marie Curie University of Paris and INSERM. The company mines epidemiological data from the INSERM's prospective cohorts.

DESCRIPTION OF THE PRODUCTS SERVICES/TECHNOLOGY

Statlife's various products and services are provided (i) by health insurers to their members, (ii) by companies to their employees or (iii) directly to pharmaceutical companies.

Statlife notably develops medical software packages for risk evaluation in diseases that depend on behavioral parameters (food habits, smoking, etc.), biological parameters and the administration of drug treatments. This personalized evaluation enables a better-informed therapeutic choice by the patient and his/her physician. Statlife also develops tools for nutritional prevention and the identification of nutritional deficits, with suggestions for possible modifications.

CEO Stéphane Ragusa

Contact details Bât. Maurice Tubiana

Institut Gustave Roussy

39, rue Camille-Desmoulins

F-94805 VILLEJUIF Cedex

Tel. +33 1 45 67 20 47

E-mail ragusa@statlife.fr

Web site www.statlife.fr

Date of founding 22/04/2004

CUSTOMER REFERENCES COLLABORATIONS/HIGHLIGHTS

Statlife collaborates with several international pharmaceutical laboratories as part of Phase IV clinical trials to improve the prescription criteria for several marketed drugs. The company has notably developed a software package for justifying the prescription of hormone substitution treatments (delimitation of the population to be screened as part of preventive treatment) by quantifying a woman's risk of breast/ovary/endometrial cancer and osteoporosis.

COLLABORATIONS SOUGHT

Statlife wishes to offer its expertise to pharmaceutical companies keen to better qualify their drugs' target populations.

Annual turnover: € 200 K > 2 patents > 4 salaried staff

Strengths: collaborations involving large, prospective cohorts. The potential to optimize drug prescription criteria during the registration or post-marketing phases.



| Medical devices |

Tech Innovation



FIELD OF ACTIVITY

Design and development of innovative products in the field of arm prostheses.

KEYWORDS

Orthopedics - Prostheses - Myoelectric devices - Arms.

Manager Vincent Artigue

Contact details Headquarters

15, rue Mademoiselle - 91140 VILLEBON-SUR-YVETTE

Office

40, rue du Pelvoux - F-91020 ÉVRY COURCOURONNES

Tel. +33 1 83 64 06 80

E-mail info@techinnovation.fr

Web site www.techinnovation.fr

Date of founding May 2000

BACKGROUND

TechInnovation was created in order to help people who are unable to use one or both arms normally. Previous, in-depth experience in robotics has enabled the company founders to design novel products.

DESCRIPTION OF THE PRODUCTS SERVICES/TECHNOLOGY

The company's first challenges involved designing a myoelectric prosthesis for the elbow and then for the hand, as well as a new generation of myoelectric sensors. TechInnovation addresses even the apparently simplest problems, such as an assistive device for helping arthritis sufferers to open a bottle.

CUSTOMER REFERENCES COLLABORATIONS/HIGHLIGHTS

Collaboration with AFM, THALES, CEA, LISV and the Raymond Poincaré Hospital (Garches) in the study and design of an orthosis for people with muscular dystrophy. This device must enable the person to use his/her arm normally again.

COLLABORATIONS SOUGHT

Financial partners, as well as distributors to market our various products. Technical collaborations to develop new products.

Annual turnover: €300 K > 4 patents > 4 salaried staff

Strengths: dynamism, responsiveness. Understanding and analysis of the issues.



| R&D services and products |

Texcell

Texcell

FIELD OF ACTIVITY

Texcell offers fully GLP- and GMP-compliant viral safety testing and immunomonitoring services.

KEYWORDS

Viral safety testing - Viral and prion validation - Immunomonitoring - Immunoprofiling - Healthcare.

CEO Bernard Plichon

Contact details Genavenir 1 & 5

1, rue Pierre-Fontaine - F-91058 ÉVRY Cedex

Tel. +33 1 60 91 33 10

Fax +33 1 64 93 33 24

E-mail info@texcell.fr

Web site www.texcell.fr

Date of founding 28/01/2003

BACKGROUND

Texcell is a service company offering GLP- and GMP-compliant viral safety testing and immunology services. Thanks to over 20 years' experience in the performance of biosafety and viral validation tests, Texcell has evaluated a large number of products—including some that have received marketing approval from the FDA, the EMEA and the MHW. The company's expertise is acknowledged worldwide and (since 2006) has developed commercial relationships with representatives based in Japan, India and South Korea. In 2008, Texcell created a US subsidiary (Texcell Inc.), in order to strengthen its presence on the American continent.

DESCRIPTION OF THE PRODUCTS SERVICES/TECHNOLOGY

Texcell offers a full catalogue of assays for the characterization of cell banks, the batch release of cell-derived biotechnological products and

viral validation studies for evaluating the ability of industrial process steps to eliminate and/or inactivate viruses (over 30 relevant or model viruses are available) and prions.

Texcell acts both as a contract research organization and a central lab for preclinical and clinical trials. Texcell offers an immunology-dedicated technology platform with an exhaustive range of GLP assay development services (optimization and validation) for analyzing the immune response to humoral and/or cell-based mediation.

Today's compound development timelines have to be as short as possible. Viral safety testing, viral validation studies and clinical studies must be continually improved, in order to optimize the therapeutic strategy. The company acts as a true partner for its customers and the staff is committed to offering the right experimental protocols and tools.

> 45 salaried staff

Strengths: an international service company that is responsive and has a close relationship with its customers. Expertise in virology and immunology.

Innovation assets: a specialist in viral and prion safety.

Other facts: as an expert provider in virology, Texcell evaluates the viral safety of recombinant proteins, monoclonal antibodies, medical devices and other products of animal or human origin (such as blood-derived products, heparins, hyaluronic acid and collagens). The company also has expertise in immunomonitoring. Texcell develops and validates assays that monitor the immune response to cell-based and/or humoral mediation in clinical trials (ELISA, cytometry, neutralizing serums, hemagglutination inhibition assays, bioassays, Luminex).



| Medical devices |

Theraclion



FIELD OF ACTIVITY

The development, manufacture and commercialization of medical devices for the non-invasive treatment of tissues with high-intensity, focused ultrasound (HIFU).

KEYWORDS

Ultrasound - Parathyroid - Medical instrumentation - Therapy.

President Jean-Yves Burel

CEO Ismael Nujally

CSO François Lacoste

Contact details Paris Santé Cochin

29, rue du Faubourg-Saint-Jacques - F-75014 PARIS

Tel. +33 1 53 10 30 90

E-mail contact@theraclion.fr

Web site www.theraclion.fr

Date of founding 05/08/2004

BACKGROUND

August 2004: Theraclion is founded on the basis of work performed by INSERM researchers and the company EDAP. April 2005: Truffle Venture becomes a shareholder, enabling continuation of Theraclion's technical and clinical development.

DESCRIPTION OF THE PRODUCTS SERVICES/TECHNOLOGY

The Th-One is a HIFU-based system for the non-invasive, ambulatory treatment of tissues. It is used to treat certain disease conditions of the neck (notably thyroid nodules and the hyperparathyroidism).

CUSTOMER REFERENCES COLLABORATIONS/HIGHLIGHTS

- November 2007: Thyros obtains the CE mark.
- December 2008: OSEO awards an €8.5 M grant-in-aid.

COLLABORATIONS SOUGHT

Industrial partners.



> 24 patent families > 10 salaried staff

Strengths: innovative, well-characterized technology. A significant market with unmet needs in the treatment of hyperparathyroidism; a strong financial partner.

Innovation assets: non-invasive tissue treatment.



| Therapeutics |

Vaxon Biotech

VAXON Biotech



FIELD OF ACTIVITY

A biopharmaceutical company developing innovative cancer therapeutics (notably for lung, liver, prostate, breast and colon cancer).

KEYWORDS

Optimized cryptic peptides - Immunotherapy - Vaccine - Oncology.

Chairman Jean-Pierre Kinet

CEO François Vallet

CSO Kostas Kosmatopoulos

Contact details Tour CIT, BP 191

3, rue de l'Arrivée - F-75749 PARIS 15^e

Tel. +33 1 45 88 67 62

E-mail kkosmatopoulos@vaxon-biotech.com

Web site www.vaxon-biotech.com

Date of founding 08/01/2004

BACKGROUND

The company is based on an invention originally patented by Dr Kostas Kosmatopoulos and his research group at Institut Gustave Roussy/Inserm: optimized cryptic peptides, which stimulate the immune system so that it specifically destroys tumor cells.

DESCRIPTION OF THE PRODUCTS SERVICES/TECHNOLOGY

The vaccines developed by Vaxon target antigens that are over-expressed in tumor cells and hardly expressed in healthy tissues. The company's two lead products are Vx-001 (mono-peptide) and Vx-006 (poly-peptide):

// Vx-001 has obtained orphan drug status for non-small cell lung cancer (NSCLC) from the EMA (in 2007) and the FDA (in 2009). It will enter in T4-2011 a phase II b clinical trial in NSCLC, in 5 countries in Europe.

// Vx-006, which is currently completing its regulatory preclinical studies, is due to start a Phase I/II clinical trial in prostate cancer patients in 2013.

In parallel, Vaxon is developing a portfolio of cancer therapeutics for all the main HLA allotypes.

CUSTOMER REFERENCES COLLABORATIONS/HIGHLIGHTS

Vx-001 has completed a phase I/II clinical trial (116 patients) and demonstrated excellent safety, a high immune response rate (70% of patients are responders) and initial proof of efficacy.


COLLABORATIONS SOUGHT

Vaxon Biotech's technology and R&D are available for strategic alliances.

> 8 patent families > 8 patents granted in Europe and in US > 4 salaried staff

Strengths: a vaccine in advanced clinical development (Phase II b).

Innovation assets: optimized cryptic peptides.



| Therapeutics |

Viroxis

FIELD OF ACTIVITY

Viroxis designs and develops vaccines and drugs against human or animal retroviral pathogens, notably the HIV retrovirus that causes AIDS.

KEYWORDS

Retrovirus - Prophylactic and therapeutic vaccines - Antiviral compounds.

President Anne-Catherine Jouanneau

Chairman of the Scientific Council

Thierry Heidmann

Contact details 11, rue Édouard-Detaille - F-75017 PARIS

Tel. +33 1 43 26 21 99

E-mails ac_jouanneau@noos.fr

heidmann@ig.fr

Date of founding 25/11/2005

BACKGROUND

Work at the CNRS UMR8122 research unit (headed by Thierry Heidmann) at the Gustave Roussy Institute has identified retroviral protein domains that have immunosuppressant activity. Targeted mutations have been used to very significantly increase the immunogenicity of the corresponding viral proteins.

DESCRIPTION OF THE PRODUCTS SERVICES/TECHNOLOGY

On the basis of UMR8122's work, Viroxis is developing (i) antigens and optimizing vaccines for HIV and other human or animal retroviruses and (ii) drug candidates that neutralize the identified domains.

CUSTOMER REFERENCES COLLABORATIONS/HIGHLIGHTS

Viroxis' development work and future products are protected by 4 proprietary or exclusively licensed patent families.

A license signed end 2010 with an international animal Health group, leader in the field, will give access to market a new animal vaccine mid 2012.



> 4 patent families > 3 salaried staff



| Therapeutics |

VitamFero



FIELD OF ACTIVITY

Design and development of new vaccines via exploitation of a patented technology platform based on a live and attenuated strain of *Toxoplasma gondii*.

KEYWORDS

Attenuated live vaccines - Toxoplasmosis - Neosporosis - Cryptosporidiosis - Coccidiosis - Leishmaniosis - Apicomplexa.

BACKGROUND

VitamFero was spun out of academic work performed at the UMR 483 research unit (François-Rabelais University of Tours/INRA), in collaboration with the CNRS. The company's founders are committed to exploiting the Toxo KO live and attenuated, patented vaccine strain of *Toxoplasma gondii*.

DESCRIPTION OF THE PRODUCTS SERVICES/TECHNOLOGY

Toxo KO live and attenuated strain results from the complete elimination of *T. gondii*'s two virulence genes, it remains strongly immunogenic but lacks any pathogenic properties. These characteristics make Toxo KO an ideal tool for developing a veterinary and human vaccine against congenital toxoplasmosis. Toxo KO also serves as a gene expression vector that enables other parasitic pathogens to be targeted.

CUSTOMER REFERENCES COLLABORATIONS/HIGHLIGHTS

VitamFero was founded on the basis of its success in the French Ministry of Research's 2005 business plan competition for innovative companies. In 2008, the signature of exclusive, worldwide license agreements with François-Rabelais University of Tours, the INRA and the CNRS and sub-licensing and distribution agreements with one of world leaders in the veterinary healthcare sector constituted key milestones in the company's development. Beyond an aggregate of over €2 M grants and refundable aids, in 2008, VitamFero secured the support of a group of Business Angels (i.e. "Val de France Angels"), then in early 2011, of venture capitalists.

COLLABORATIONS SOUGHT

In addition to upstream, collaborative R&D partners (with a horizon of a couple of years), VitamFero is seeking one or more sub-licensees for promotion, commercialization and distribution of its vaccines.

Chairman & CEO Dr. Pascal Breton

R&D Director Dr. Édouard Seche

Contact details Pépinière Genopole® Entreprises

4, rue Pierre-Fontaine – F-91058 ÉVRY Cedex

Tel. +33 6 82 65 47 69

+33 2 47 36 70 47

Fax +33 2 47 36 70 50

E-mail p.breton@vitamfero.com

Web site www.vitamfero.com

Date of founding 27/10/2005

Annual turnover: > 21 patents > 8 salaried staff

Strengths: a technology platform which provides many opportunities for designing and developing novel live attenuated vaccines. A business model which uses the veterinary market to fund the development of vaccines for human healthcare.

Innovation assets: a safe and effective approach which is being strongly encouraged by the EMEA.

Other facts: perfectly identified and validated markets in both the veterinary and human healthcare sectors.



WatchFrog

WATCHFROG

FIELD OF ACTIVITY

WatchFrog markets *in vivo* biotechnological solutions for the environmental risk assessment and the evaluation of the therapeutic, toxic or pollutant potential of all types of chemical or biological compounds.

KEYWORDS

In vivo - Toxicity - Environment - Endocrine - Nervous system.

BACKGROUND

WatchFrog is a service and contract testing provider for several major industrial customers, all of whom are world leaders in their respective fields: water, energy, consumer goods, fine chemicals and pharmaceuticals. WatchFrog has a routine screening platform that meets the quality standards required by its industrial customers.

DESCRIPTION OF THE PRODUCTS SERVICES/TECHNOLOGY

/// In the environmental sector, WatchFrog offers modular systems for the real-time monitoring of the presence of pollutants in industrial effluent.

/// For the environmental, chemicals and pharmaceutical sectors, WatchFrog has its own automated screening platform (with a throughput of several hundred samples over a few hours). Moreover, WatchFrog sells routine tests for screening for the endocrine-disrupting properties of chemical compounds under the European Union's REACH legislation and Water Framework Directive.

/// WatchFrog can also create dedicated disease models for the pharmaceutical industry.

CUSTOMER REFERENCES COLLABORATIONS/HIGHLIGHTS

- /// Collaboration agreement with the Environmental Protection Agency (USA EPA) as part of the TOXCAST program for prioritizing the toxicity testing of large numbers of chemicals.
- /// Participation to two projects of the French National Research Program on Endocrine Disruptors (PNPRE).
- /// Coordination of the Alternative Model for Brain Research (AMBRé) project accredited by the Medicen Paris Region cluster; the goal is to accelerate the development of therapeutic solutions for neurodegenerative or demyelinating diseases.

COLLABORATIONS SOUGHT

In view of the flexibility of WatchFrog's technology, we are looking for new industrial partners to take up new challenges in lead optimization or environmental risk evaluation.

CEO Gregory Lemkine

Contact details

Bât Genavenir 3
1, rue Pierre-Fontaine - F-91058 ÉVRY Cedex

Tel. +33 1 69 36 11 15

E-mail info@watchfrog.fr

Web site www.watchfrog.fr

Date of founding November 2005

Annual turnover: €950 K > 14 salaried staff

Strengths: miniature, industrializable vertebrate models. A technology platform that complies with international quality standards for the production of aquatic material and molecular screening.

Innovation assets: real-time monitoring of environmental risks on industrial sites.

Other facts: the creation of custom disease models.



| Therapeutics |

Wittycell

Wittycell
Boosting your immune system

FIELD OF ACTIVITY

Development of vaccine adjuvants.

KEYWORDS

Adjuvant - Vaccine - NKT cells - Healthcare.

BACKGROUND

Wittycell uses a proprietary technology (in licensed from three American institutes) based on the stimulation of NKTi cells) to develop novel vaccine adjuvants.

DESCRIPTION OF THE PRODUCTS SERVICES/ TECHNOLOGY

Wittycell developed Immunomodulator adjuvants based on NKT agonist glycolipids, for therapeutic and prophylactic vaccines against infectious diseases and cancer.

CUSTOMER REFERENCES COLLABORATIONS/ HIGHLIGHTS

Wittycell SAS has strong intellectual property position with major partnerships including the Jean Godinot Institute (France), the Institute for Medical Immunology (Belgium), the Scripps Research Institute (USA), the University of Chicago (USA) and the Brigham Young University (USA), and several private pharmaceutical companies (undisclosed information).

The first three immunomodulators leads are in preclinical development. The manufacturing process had been scaled up for million doses. The first GMP batch had been released recently for further clinical development.

Chairman Vincent Serra

CEO & CSO Miguel Sieler

Contact details Siège

8 bis, rue du Gabriel-Voisin - 51100 REIMS

Établissement secondaire

4, rue Pierre-Fontaine - F-91058 ÉVRY Cedex

Tel. +33 1 60 87 89 00

Tel. +33 1 60 87 89 99

E-mail vserra@wittycell.com

Web site www.wittycell.com

Date of founding August 2005

COLLABORATIONS SOUGHT

Pharma/vaccine companies looking for novel adjuvants.



> 28 patents > 10 salaried staff

Strengths: a network of international experts in biotechnology, molecular modeling, cell biology, clinical trials and virology. Proof of concept (*in vivo* efficacy) in many indications. GMP adjuvant ready to use for vaccine clinical development.



| R&D services and products |

XenTech

XenTech

FIELD OF ACTIVITY

XenTech is an innovative biotech company which specializes in the preclinical evaluation of cancer drugs and the identification of biomarkers and therapeutic targets.

KEYWORDS

Oncology - Preclinical expertise - Predictive models - Biomarkers - Companion tests.

President & CSO Jean Gabriel Judde

CEO Bertrand Coulomb

Operations director Pascal Leuraud

Contact details Pépinière Genopole® Entreprises
Campus 3 - 4, rue Pierre-Fontaine - F-91058 ÉVRY
Cedex

Tel. +33 1 60 87 89 80

E-mail contact@xentech.eu

Web site www.xentech.eu

Date of founding April 2006

BACKGROUND

XenTech was founded in 2006 by researchers from Institut Curie having over 15 years of experience in preclinical pharmacology in oncology. This spin-off company dedicated to biomarker discovery and preclinical evaluation of anticancer therapies is known worldwide for its expertise in the field of tumor xenografts. Located on Genopole® Campus, its experimental models are housed in the CERFE (see page 49).

DESCRIPTION OF THE PRODUCTS SERVICES/TECHNOLOGY

XenTech has an innovative experimental platform: one of the world's largest collections of solid human tumors xenografted onto immunodeficient mice. The collection is representative of the major types of cancer (breast, lung, colon, prostate) but also includes less common tumors (melanoma, ovarian cancer, pancreatic cancer, glioma).

XenTech's platform is of considerable value for translational research in oncology, notably for drug screening and the molecular characterization of sensitive tumors.

XenTech participates in the development of novel cancer therapies by offering its services, models and expertise in preclinical oncology to stakeholders in oncology research.

CUSTOMER REFERENCES COLLABORATIONS/HIGHLIGHTS

- // Partnership with the world's biggest pharmaceutical companies involved in oncology.
- // Establishment of partnerships with major French Cancer Centers.
- // Participation in OSEO's Strategic Industrial Innovation Programme "Cancer Anti-invasive Program" (CAP) which aims at developing a new therapeutic approach for invasive cancers.

COLLABORATIONS SOUGHT

- // Collaborative partnership with pharmaceutical industry on drug response biomarkers discovery programs.
- // Collaborative partnership with hospital structures to pursue development of the preclinical platform.
- // Research fee-for-service contracts with pharmaceutical companies, biotechs and academic groups for evaluating antitumor efficacy of their drug candidates.

Annual turnover: €2 M > 28 salaried staff

Strengths: a unique panel of breast cancers.

World-renowned experimental platform and scientific expertise.